JAN ANDREASBURGERJAN ANDREAS BURGER9300BURGER, JAN ANDREASAssociate Professorprns:coAuthorOfcoauthor ofFaculty Rankprns:fullNamefull nameprns:hasAuthorListauthor listprns:hasFacultyRankhas faculty rankprns:hasNetworkhas networkprns:hasPublicationVenuepublished inprns:informationResourceReferenceinformation resource referenceprns:isPrimaryPositionis primary positionprns:maxWeightmaximum weightprns:medlineTAjournal title abbreviationprns:meshDescriptorUIMeSH DescriptorUIprns:meshSemanticGroupNameMeSH semantic group nameprns:minWeightminimum weightprns:numberOfAuthorsnumber of authorsprns:numberOfConnectionsnumber of connectionsprns:numberOfPublicationsnumber of publicationsprns:personIdPerson IDprns:personInPrimaryPositionperson in primary positionprns:positionInDepartmentposition in departmentprns:positionInDivisionposition in divisionprns:predicateNodepredicate nodeprns:publicationDatepublication dateprns:similarTosimilar toprns:sortOrdersort orderprns:uniquenessWeightuniqueness weightprns:yearyearAcademic ArticleArticleDocumentbibo:pmidPubMed IdentifierAddressvivo:address1address line 1vivo:addressCitycityvivo:addressPostalCodepostal codevivo:addressStatestate or provincevivo:authorInAuthorshipselected publicationsvivo:authorRankauthor rank in publicationAuthorshipDepartmentDivisionvivo:hasResearchArearesearch areasvivo:hrJobTitleHR job titleInformation Resourcevivo:linkedAuthorlinked authorvivo:linkedInformationResourcelinked information resourcevivo:mailingAddressmailing addressvivo:personInPositionpositionsPositionvivo:positionInOrganizationposition in organizationvivo:preferredTitlepreferred titlerdf:predicatepredicaterdf:typetyperdfs:labellabelConceptAgentfoaf:firstNamefirst namefoaf:lastNamelast nameOrganizationPerson25700432Byrd JC, Furman RR, Coutre SE, Burger JA, Blum KA, Coleman M, Wierda WG, Jones JA, Zhao W, Heerema NA, Johnson AJ, Shaw Y, Bilotti E, Zhou C, James DF, O'Brien SBloodThree-year follow-up of treatment-na?ve and previously treated patients with CLL and SLL receiving single-agent ibrutinib. Blood. 2015 Apr 16; 125(16):2497-506.Blood2015-02-19T00:00:002015Three-year follow-up of treatment-na?ve and previously treated patients with CLL and SLL receiving single-agent ibrutinib.1400 Holcombe BlvdHouston77030-4008TXAuthorship 1695572Authorship 1725077Authorship 1732571Authorship 18065310Authorship 1806601Authorship 1815428Authorship 1820541Authorship 1840062Authorship 1844534Authorship 18460715Authorship 1852378Authorship 1853511Authorship 1868701Authorship 1871743Authorship 1931695Authorship 1937231Authorship 194241811807009Tsukada N, Burger JA, Zvaifler NJ, Kipps TJBloodDistinctive features of "nurselike" cells that differentiate in the context of chronic lymphocytic leukemia. Blood. 2002 Feb 01; 99(3):1030-7.Blood2002-02-01T00:00:002002Distinctive features of "nurselike" cells that differentiate in the context of chronic lymphocytic leukemia.12899713Burger JA, Spoo A, Dwenger A, Burger M, Behringer DBritish journal of haematologyCXCR4 chemokine receptors (CD184) and alpha4beta1 integrins mediate spontaneous migration of human CD34+ progenitors and acute myeloid leukaemia cells beneath marrow stromal cells (pseudoemperipolesis). Br J Haematol. 2003 Aug; 122(4):579-89.Br J Haematol2003-08-01T00:00:002003CXCR4 chemokine receptors (CD184) and alpha4beta1 integrins mediate spontaneous migration of human CD34+ progenitors and acute myeloid leukaemia cells beneath marrow stromal cells (pseudoemperipolesis).14603250Burger M, Glodek A, Hartmann T, Schmitt-Gr?ff A, Silberstein LE, Fujii N, Kipps TJ, Burger JAOncogeneFunctional expression of CXCR4 (CD184) on small-cell lung cancer cells mediates migration, integrin activation, and adhesion to stromal cells. Oncogene. 2003 Nov 06; 22(50):8093-101.Oncogene2003-11-06T00:00:002003Functional expression of CXCR4 (CD184) on small-cell lung cancer cells mediates migration, integrin activation, and adhesion to stromal cells.19074730Burger JA, Quiroga MP, Hartmann E, B?rkle A, Wierda WG, Keating MJ, Rosenwald ABloodHigh-level expression of the T-cell chemokines CCL3 and CCL4 by chronic lymphocytic leukemia B cells in nurselike cell cocultures and after BCR stimulation. Blood. 2009 Mar 26; 113(13):3050-8.Blood2008-12-12T00:00:002008High-level expression of the T-cell chemokines CCL3 and CCL4 by chronic lymphocytic leukemia B cells in nurselike cell cocultures and after BCR stimulation.19335276Burger JA, Stewart DJExpert opinion on investigational drugsCXCR4 chemokine receptor antagonists: perspectives in SCLC. Expert Opin Investig Drugs. 2009 Apr; 18(4):481-90.Expert Opin Investig Drugs2009-04-01T00:00:002009CXCR4 chemokine receptor antagonists: perspectives in SCLC.20501831Quiroga MP, Burger JACancer researchBCR-mediated decrease of CXCR4 and CD62L in CLL. Cancer Res. 2010 Jun 15; 70(12):5194; author reply 5195.Cancer Res2010-05-25T00:00:002010BCR-mediated decrease of CXCR4 and CD62L in CLL.20883788Burger JASeminars in cancer biologyChemokines and chemokine receptors in chronic lymphocytic leukemia (CLL): from understanding the basics towards therapeutic targeting. Semin Cancer Biol. 2010 Dec; 20(6):424-30.Semin Cancer Biol2010-09-29T00:00:002010Chemokines and chemokine receptors in chronic lymphocytic leukemia (CLL): from understanding the basics towards therapeutic targeting.21504328Burger JA, Stewart DJ, Wald O, Peled AExpert review of anticancer therapyPotential of CXCR4 antagonists for the treatment of metastatic lung cancer. Expert Rev Anticancer Ther. 2011 Apr; 11(4):621-30.Expert Rev Anticancer Ther2011-04-01T00:00:002011Potential of CXCR4 antagonists for the treatment of metastatic lung cancer.24357428Burger JACurrent hematologic malignancy reportsBruton's tyrosine kinase (BTK) inhibitors in clinical trials. Curr Hematol Malig Rep. 2014 Mar; 9(1):44-9.Curr Hematol Malig Rep2014-03-01T00:00:002014Bruton's tyrosine kinase (BTK) inhibitors in clinical trials.Experimental TherapeuticsLeukemiaMD AndersonVARSHA VGANDHIVARSHA V GANDHI8582GANDHI, VARSHA VProfessorJORGE ECORTESJORGE E CORTES8637CORTES, JORGE EProfessorWILLIAM GWIERDAWILLIAM G WIERDA8937WIERDA, WILLIAM GProfessorHAGOP MKANTARJIANHAGOP M KANTARJIAN8501KANTARJIAN, HAGOP MProfessor20.91890.00475909629research areas8.482960.025504897coauthor of934.26867.658560similar to11324selected publicationsZEEVESTROVZEEV ESTROV8622ESTROV, ZEEVProfessorNITINJAINNITIN JAIN9432JAIN, NITINAssistant ProfessorALESSANDRAFERRAJOLIALESSANDRA FERRAJOLI8776FERRAJOLI, ALESSANDRAProfessorAuthorship 2168141Authorship 2191851Authorship 2221423Authorship 2221931Authorship 2222435Authorship 2240918Authorship 2256071Authorship 2262884Authorship 2264692Authorship 2283051Authorship 2289161Authorship 2295085Authorship 2297222Authorship 2298112Authorship 2299931Authorship 23016312Authorship 23057910Authorship 2307951Authorship 23090911Authorship 2309631Authorship 23119010Authorship 23122211Authorship 23187511Authorship 2320491Authorship 2320834Authorship 2321208Authorship 2333351Authorship 2338811Authorship 23433413Authorship 23447414Authorship 2348741Authorship 23519149333603Sach M, Burger JA, Engelhardt A, Ketelsen UP, Schollmeyer PDer Internist[Temporary hemiparesis and Raynaud symptoms in eosinophilic fasciitis]. Internist (Berl). 1997 Jul; 38(7):688-91.Internist (Berl)1997-07-01T00:00:001997[Temporary hemiparesis and Raynaud symptoms in eosinophilic fasciitis].12002747Burger JA, Kipps TJLeukemia & lymphomaChemokine receptors and stromal cells in the homing and homeostasis of chronic lymphocytic leukemia B cells. Leuk Lymphoma. 2002 Mar; 43(3):461-6.Leuk Lymphoma2002-03-01T00:00:002002Chemokine receptors and stromal cells in the homing and homeostasis of chronic lymphocytic leukemia B cells.15180856Zeiser R, Mikesch K, Fisch P, Schaefer HE, Burger JABritish journal of haematologyExtramedullary plasmocytoma with local amyloidosis presenting as a lump on the lip. Br J Haematol. 2004 Jun; 125(6):679.Br J Haematol2004-06-01T00:00:002004Extramedullary plasmocytoma with local amyloidosis presenting as a lump on the lip.15688008Burger M, Hartmann T, Burger JA, Schraufstatter IOncogeneKSHV-GPCR and CXCR2 transforming capacity and angiogenic responses are mediated through a JAK2-STAT3-dependent pathway. Oncogene. 2005 Mar 17; 24(12):2067-75.Oncogene2005-03-17T00:00:002005KSHV-GPCR and CXCR2 transforming capacity and angiogenic responses are mediated through a JAK2-STAT3-dependent pathway.15905192Burger M, Hartmann T, Krome M, Rawluk J, Tamamura H, Fujii N, Kipps TJ, Burger JABloodSmall peptide inhibitors of the CXCR4 chemokine receptor (CD184) antagonize the activation, migration, and antiapoptotic responses of CXCL12 in chronic lymphocytic leukemia B cells. Blood. 2005 Sep 01; 106(5):1824-30.Blood2005-05-19T00:00:002005Small peptide inhibitors of the CXCR4 chemokine receptor (CD184) antagonize the activation, migration, and antiapoptotic responses of CXCL12 in chronic lymphocytic leukemia B cells.16269611Burger JA, Kipps TJBloodCXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment. Blood. 2006 Mar 01; 107(5):1761-7.Blood2005-11-03T00:00:002005CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment.17234265Burger JALeukemia researchNo cell is an island unto itself: the stromal microenvironment in chronic lymphocytic leukemia. Leuk Res. 2007 Jul; 31(7):887-8.Leuk Res2007-01-17T00:00:002007No cell is an island unto itself: the stromal microenvironment in chronic lymphocytic leukemia.17652619B?rkle A, Niedermeier M, Schmitt-Gr?ff A, Wierda WG, Keating MJ, Burger JABloodOverexpression of the CXCR5 chemokine receptor, and its ligand, CXCL13 in B-cell chronic lymphocytic leukemia. Blood. 2007 Nov 01; 110(9):3316-25.Blood2007-07-25T00:00:002007Overexpression of the CXCR5 chemokine receptor, and its ligand, CXCL13 in B-cell chronic lymphocytic leukemia.18836097Balakrishnan K, Burger JA, Wierda WG, Gandhi VBloodAT-101 induces apoptosis in CLL B cells and overcomes stromal cell-mediated Mcl-1 induction and drug resistance. Blood. 2009 Jan 01; 113(1):149-53.Blood2008-10-03T00:00:002008AT-101 induces apoptosis in CLL B cells and overcomes stromal cell-mediated Mcl-1 induction and drug resistance.19762501Burger JA, Gandhi VBloodThe lymphatic tissue microenvironments in chronic lymphocytic leukemia: in vitro models and the significance of CD40-CD154 interactions. Blood. 2009 Sep 17; 114(12):2560-1; author reply 2561-2.Blood2009-09-17T00:00:002009The lymphatic tissue microenvironments in chronic lymphocytic leukemia: in vitro models and the significance of CD40-CD154 interactions.20442367Balakrishnan K, Burger JA, Quiroga MP, Henneberg M, Ayres ML, Wierda WG, Gandhi VBloodInfluence of bone marrow stromal microenvironment on forodesine-induced responses in CLL primary cells. Blood. 2010 Aug 19; 116(7):1083-91.Blood2010-05-04T00:00:002010Influence of bone marrow stromal microenvironment on forodesine-induced responses in CLL primary cells.20671131Burger JABloodAngiopoietin-2 in CLL. Blood. 2010 Jul 29; 116(4):508-9.Blood2010-07-29T00:00:002010Angiopoietin-2 in CLL.20807980Ponader S, Burger JAHaematologicaModeling the marrow stem cell niche in vitro: is proximity the key to reproduction? Haematologica. 2010 Sep; 95(9):e5.Haematologica2010-09-01T00:00:002010Modeling the marrow stem cell niche in vitro: is proximity the key to reproduction?21456010Konoplev S, Jorgensen JL, Thomas DA, Lin E, Burger J, Kantarjian HM, Andreeff M, Medeiros LJ, Konopleva MCancerPhosphorylated CXCR4 is associated with poor survival in adults with B-acute lymphoblastic leukemia. Cancer. 2011 Oct 15; 117(20):4689-95.Cancer2011-03-31T00:00:002011Phosphorylated CXCR4 is associated with poor survival in adults with B-acute lymphoblastic leukemia.21803855Hoellenriegel J, Meadows SA, Sivina M, Wierda WG, Kantarjian H, Keating MJ, Giese N, O'Brien S, Yu A, Miller LL, Lannutti BJ, Burger JABloodThe phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia. Blood. 2011 Sep 29; 118(13):3603-12.Blood2011-07-29T00:00:002011The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia.21945516Burger JA, Ford RJSeminars in cancer biologyThe microenvironment in mantle cell lymphoma: cellular and molecular pathways and emerging targeted therapies. Semin Cancer Biol. 2011 Nov; 21(5):308-12.Semin Cancer Biol2011-09-18T00:00:002011The microenvironment in mantle cell lymphoma: cellular and molecular pathways and emerging targeted therapies.21969505Wierda WG, O'Brien S, Wang X, Faderl S, Ferrajoli A, Do KA, Garcia-Manero G, Cortes J, Thomas D, Koller CA, Burger JA, Lerner S, Schlette E, Abruzzo L, Kantarjian HM, Keating MJJournal of clinical oncology : official journal of the American Society of Clinical OncologyMultivariable model for time to first treatment in patients with chronic lymphocytic leukemia. J Clin Oncol. 2011 Nov 01; 29(31):4088-95.J Clin Oncol2011-10-03T00:00:002011Multivariable model for time to first treatment in patients with chronic lymphocytic leukemia.22058222Jain P, Javdan M, Feger FK, Chiu PY, Sison C, Damle RN, Bhuiya TA, Sen F, Abruzzo LV, Burger JA, Rosenwald A, Allen SL, Kolitz JE, Rai KR, Chiorazzi N, Sherry BHaematologicaTh17 and non-Th17 interleukin-17-expressing cells in chronic lymphocytic leukemia: delineation, distribution, and clinical relevance. Haematologica. 2012 Apr; 97(4):599-607.Haematologica2011-11-04T00:00:002011Th17 and non-Th17 interleukin-17-expressing cells in chronic lymphocytic leukemia: delineation, distribution, and clinical relevance.22105489Burger JACurrent hematologic malignancy reportsInhibiting B-cell receptor signaling pathways in chronic lymphocytic leukemia. Curr Hematol Malig Rep. 2012 Mar; 7(1):26-33.Curr Hematol Malig Rep2012-03-01T00:00:002012Inhibiting B-cell receptor signaling pathways in chronic lymphocytic leukemia.22160019Burger JAHematology. American Society of Hematology. Education ProgramNurture versus nature: the microenvironment in chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program. 2011; 2011:96-103.Hematology Am Soc Hematol Educ Program2011-01-01T00:00:002011Nurture versus nature: the microenvironment in chronic lymphocytic leukemia.22180443Ponader S, Chen SS, Buggy JJ, Balakrishnan K, Gandhi V, Wierda WG, Keating MJ, O'Brien S, Chiorazzi N, Burger JABloodThe Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo. Blood. 2012 Feb 02; 119(5):1182-9.Blood2011-12-16T00:00:002011The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo.22282348Faderl S, Ravandi F, Huang X, Wang X, Jabbour E, Garcia-Manero G, Kadia T, Ferrajoli A, Konopleva M, Borthakur G, Burger J, Feliu J, Kantarjian HMCancerClofarabine plus low-dose cytarabine followed by clofarabine plus low-dose cytarabine alternating with decitabine in acute myeloid leukemia frontline therapy for older patients. Cancer. 2012 Sep 15; 118(18):4471-7.Cancer2012-01-26T00:00:002012Clofarabine plus low-dose cytarabine followed by clofarabine plus low-dose cytarabine alternating with decitabine in acute myeloid leukemia frontline therapy for older patients.22422826Eghtedar A, Verstovsek S, Estrov Z, Burger J, Cortes J, Bivins C, Faderl S, Ferrajoli A, Borthakur G, George S, Scherle PA, Newton RC, Kantarjian HM, Ravandi FBloodPhase 2 study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including postmyeloproliferative neoplasm acute myeloid leukemia. Blood. 2012 May 17; 119(20):4614-8.Blood2012-03-15T00:00:002012Phase 2 study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including postmyeloproliferative neoplasm acute myeloid leukemia.22534616Jabbour E, Garcia-Manero G, Cortes J, Ravandi F, Plunkett W, Gandhi V, Faderl S, O'Brien S, Borthakur G, Kadia T, Burger J, Konopleva M, Brandt M, Huang X, Kantarjian HClinical lymphoma, myeloma & leukemiaTwice-daily fludarabine and cytarabine combination with or without gentuzumab ozogamicin is effective in patients with relapsed/refractory acute myeloid leukemia, high-risk myelodysplastic syndrome, and blast- phase chronic myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2012 Aug; 12(4):244-51.Clin Lymphoma Myeloma Leuk2012-04-24T00:00:002012Twice-daily fludarabine and cytarabine combination with or without gentuzumab ozogamicin is effective in patients with relapsed/refractory acute myeloid leukemia, high-risk myelodysplastic syndrome, and blast- phase chronic myeloid leukemia.23264597Burger JA, Montserrat EBloodComing full circle: 70 years of chronic lymphocytic leukemia cell redistribution, from glucocorticoids to inhibitors of B-cell receptor signaling. Blood. 2013 Feb 28; 121(9):1501-9.Blood2012-12-20T00:00:002012Coming full circle: 70 years of chronic lymphocytic leukemia cell redistribution, from glucocorticoids to inhibitors of B-cell receptor signaling.23270003Badoux XC, Keating MJ, Wen S, Wierda WG, O'Brien SM, Faderl S, Sargent R, Burger JA, Ferrajoli AJournal of clinical oncology : official journal of the American Society of Clinical OncologyPhase II study of lenalidomide and rituximab as salvage therapy for patients with relapsed or refractory chronic lymphocytic leukemia. J Clin Oncol. 2013 Feb 10; 31(5):584-91.J Clin Oncol2012-12-26T00:00:002012Phase II study of lenalidomide and rituximab as salvage therapy for patients with relapsed or refractory chronic lymphocytic leukemia.23480620Burger JAExpert opinion on medical diagnosticsThe times they are a-changin': prognostic markers in the new era of BCR-targeting therapies for CLL. Expert Opin Med Diagn. 2012 Jan; 6(1):49-57.Expert Opin Med Diagn2011-11-28T00:00:002011The times they are a-changin': prognostic markers in the new era of BCR-targeting therapies for CLL.23613521Ravandi F, Alattar ML, Grunwald MR, Rudek MA, Rajkhowa T, Richie MA, Pierce S, Daver N, Garcia-Manero G, Faderl S, Nazha A, Konopleva M, Borthakur G, Burger J, Kadia T, Dellasala S, Andreeff M, Cortes J, Kantarjian H, Levis MBloodPhase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation. Blood. 2013 Jun 06; 121(23):4655-62.Blood2013-04-23T00:00:002013Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation.23928062Burger JA, Chiorazzi NTrends in immunologyB cell receptor signaling in chronic lymphocytic leukemia. Trends Immunol. 2013 Dec; 34(12):592-601.Trends Immunol2013-08-05T00:00:002013B cell receptor signaling in chronic lymphocytic leukemia.24583795Konopleva MY, Walter RB, Faderl SH, Jabbour EJ, Zeng Z, Borthakur G, Huang X, Kadia TM, Ruvolo PP, Feliu JB, Lu H, Debose L, Burger JA, Andreeff M, Liu W, Baggerly KA, Kornblau SM, Doyle LA, Estey EH, Kantarjian HMClinical cancer research : an official journal of the American Association for Cancer ResearchPreclinical and early clinical evaluation of the oral AKT inhibitor, MK-2206, for the treatment of acute myelogenous leukemia. Clin Cancer Res. 2014 Apr 15; 20(8):2226-35.Clin Cancer Res2014-02-28T00:00:002014Preclinical and early clinical evaluation of the oral AKT inhibitor, MK-2206, for the treatment of acute myelogenous leukemia.24705492Strati P, Keating MJ, O'Brien SM, Burger J, Ferrajoli A, Jain N, Tambaro FP, Estrov Z, Jorgensen J, Challagundla P, Faderl SH, Wierda WGBloodEradication of bone marrow minimal residual disease may prompt early treatment discontinuation in CLL. Blood. 2014 Jun 12; 123(24):3727-32.Blood2014-04-04T00:00:002014Eradication of bone marrow minimal residual disease may prompt early treatment discontinuation in CLL.25150798Burger JA, Keating MJ, Wierda WG, Hartmann E, Hoellenriegel J, Rosin NY, de Weerdt I, Jeyakumar G, Ferrajoli A, Cardenas-Turanzas M, Lerner S, Jorgensen JL, Nogueras-Gonz?lez GM, Zacharian G, Huang X, Kantarjian H, Garg N, Rosenwald A, O'Brien SThe Lancet. OncologySafety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study. Lancet Oncol. 2014 Sep; 15(10):1090-9.Lancet Oncol2014-08-20T00:00:002014Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study.Authorship 2399771Authorship 2466272Authorship 2483971Authorship 2523121Authorship 2529701Authorship 25351411Authorship 2546508Authorship 2559451Authorship 2572072Authorship 2572901Authorship 2578111Authorship 2587801Authorship 2603813Authorship 26041311Authorship 2605411Authorship 2610835Authorship 2616078Authorship 2616662Authorship 262057109093733Burger JA, Ochs A, Wirth K, Berger DP, Mertelsmann R, Engelhardt R, Roessle M, Haag KAnnals of oncology : official journal of the European Society for Medical OncologyThe transjugular stent implantation for the treatment of malignant portal and hepatic vein obstruction in cancer patients. Ann Oncol. 1997 Feb; 8(2):200-2.Ann Oncol1997-02-01T00:00:001997The transjugular stent implantation for the treatment of malignant portal and hepatic vein obstruction in cancer patients.15806155Hartmann TN, Burger JA, Glodek A, Fujii N, Burger MOncogeneCXCR4 chemokine receptor and integrin signaling co-operate in mediating adhesion and chemoresistance in small cell lung cancer (SCLC) cells. Oncogene. 2005 Jun 23; 24(27):4462-71.Oncogene2005-06-23T00:00:002005CXCR4 chemokine receptor and integrin signaling co-operate in mediating adhesion and chemoresistance in small cell lung cancer (SCLC) cells.17107924Burger JA, Schmitt-Gr?ff A, B?rkle A, Seiler L, Finke JLeukemia & lymphomaImatinib mesylate-induced long-term remission in extra-medullary T-cell lymphoid blastic phase of chronic myelogenous leukemia. Leuk Lymphoma. 2006 Nov; 47(11):2427-30.Leuk Lymphoma2006-11-01T00:00:002006Imatinib mesylate-induced long-term remission in extra-medullary T-cell lymphoid blastic phase of chronic myelogenous leukemia.19091405Burger JALeukemia researchCXCR4 in acute myelogenous leukemia (AML): when too much attraction is bad for you. Leuk Res. 2009 Jun; 33(6):747-8.Leuk Res2008-12-17T00:00:002008CXCR4 in acute myelogenous leukemia (AML): when too much attraction is bad for you.19224852Wierda WG, O'Brien S, Wang X, Faderl S, Ferrajoli A, Do KA, Garcia-Manero G, Cortes J, Thomas D, Koller C, Burger J, Lerner S, Kantarjian H, Keating MJournal of clinical oncology : official journal of the American Society of Clinical OncologyCharacteristics associated with important clinical end points in patients with chronic lymphocytic leukemia at initial treatment. J Clin Oncol. 2009 Apr 01; 27(10):1637-43.J Clin Oncol2009-02-17T00:00:002009Characteristics associated with important clinical end points in patients with chronic lymphocytic leukemia at initial treatment.19636060Burger JA, Ghia P, Rosenwald A, Caligaris-Cappio FBloodThe microenvironment in mature B-cell malignancies: a target for new treatment strategies. Blood. 2009 Oct 15; 114(16):3367-75.Blood2009-07-27T00:00:002009The microenvironment in mature B-cell malignancies: a target for new treatment strategies.19895616Alatrash G, Albitar M, O'Brien S, Wang X, Manshouri T, Faderl S, Ferrajoli A, Burger J, Garcia-Manero G, Kantarjian HM, Lerner S, Keating MJ, Wierda WGBritish journal of haematologyCirculating CD52 and CD20 levels at end of treatment predict for progression and survival in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab (FCR). Br J Haematol. 2010 Feb; 148(3):386-93.Br J Haematol2009-11-06T00:00:002009Circulating CD52 and CD20 levels at end of treatment predict for progression and survival in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab (FCR).21438839Burger JA, Sivina M, Ravandi FLeukemia & lymphomaThe microenvironment in hairy cell leukemia: pathways and potential therapeutic targets. Leuk Lymphoma. 2011 Jun; 52 Suppl 2:94-8.Leuk Lymphoma2011-03-25T00:00:002011The microenvironment in hairy cell leukemia: pathways and potential therapeutic targets.21830996Burger JALeukemia & lymphomaDisrupting the food chain in B cell lymphomas: co-operation between CXCR4 antagonists and antibodies. Leuk Lymphoma. 2012 Jan; 53(1):3-4.Leuk Lymphoma2011-09-23T00:00:002011Disrupting the food chain in B cell lymphomas: co-operation between CXCR4 antagonists and antibodies.22493212Burger JABloodBRAF mutation: supporting diversity in HCL. Blood. 2012 Apr 05; 119(14):3193-4.Blood2012-04-05T00:00:002012BRAF mutation: supporting diversity in HCL.22541616Saintigny P, Burger JADiscovery medicineRecent advances in non-small cell lung cancer biology and clinical management. Discov Med. 2012 Apr; 13(71):287-97.Discov Med2012-04-01T00:00:002012Recent advances in non-small cell lung cancer biology and clinical management.22960555Burger JACurrent opinion in oncologyTargeting the microenvironment in chronic lymphocytic leukemia is changing the therapeutic landscape. Curr Opin Oncol. 2012 Nov; 24(6):643-9.Curr Opin Oncol2012-11-01T00:00:002012Targeting the microenvironment in chronic lymphocytic leukemia is changing the therapeutic landscape.23766457Burger JABloodOsteopontin: an unhealthy sleep remedy for ALL. Blood. 2013 Jun 13; 121(24):4814-5.Blood2013-06-13T00:00:002013Osteopontin: an unhealthy sleep remedy for ALL.23913852Falchi L, Kantarjian HM, Wang X, Verma D, Quint?s-Cardama A, O'Brien S, Jabbour EJ, Ravandi-Kashani F, Borthakur G, Garcia-Manero G, Verstovsek S, Burger JA, Luthra R, Cortes JEAmerican journal of hematologySignificance of deeper molecular responses in patients with chronic myeloid leukemia in early chronic phase treated with tyrosine kinase inhibitors. Am J Hematol. 2013 Dec; 88(12):1024-9.Am J Hematol2013-09-12T00:00:002013Significance of deeper molecular responses in patients with chronic myeloid leukemia in early chronic phase treated with tyrosine kinase inhibitors.23943357Strati P, Wierda W, Burger J, Ferrajoli A, Tam C, Lerner S, Keating MJ, O'Brien SCancerMyelosuppression after frontline fludarabine, cyclophosphamide, and rituximab in patients with chronic lymphocytic leukemia: analysis of persistent and new-onset cytopenia. Cancer. 2013 Nov 01; 119(21):3805-11.Cancer2013-08-13T00:00:002013Myelosuppression after frontline fludarabine, cyclophosphamide, and rituximab in patients with chronic lymphocytic leukemia: analysis of persistent and new-onset cytopenia.24323900ten Hacken E, Burger JAClinical cancer research : an official journal of the American Association for Cancer ResearchMolecular pathways: targeting the microenvironment in chronic lymphocytic leukemia--focus on the B-cell receptor. Clin Cancer Res. 2014 Feb 01; 20(3):548-56.Clin Cancer Res2013-12-09T00:00:002013Molecular pathways: targeting the microenvironment in chronic lymphocytic leukemia--focus on the B-cell receptor.24697238Sivina M, Kreitman RJ, Arons E, Ravandi F, Burger JABritish journal of haematologyThe bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) blocks hairy cell leukaemia survival, proliferation and B cell receptor signalling: a new therapeutic approach. Br J Haematol. 2014 Jul; 166(2):177-88.Br J Haematol2014-04-02T00:00:002014The bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) blocks hairy cell leukaemia survival, proliferation and B cell receptor signalling: a new therapeutic approach.24778152Rozovski U, Wu JY, Harris DM, Liu Z, Li P, Hazan-Halevy I, Ferrajoli A, Burger JA, O'Brien S, Jain N, Verstovsek S, Wierda WG, Keating MJ, Estrov ZBloodStimulation of the B-cell receptor activates the JAK2/STAT3 signaling pathway in chronic lymphocytic leukemia cells. Blood. 2014 Jun 12; 123(24):3797-802.Blood2014-04-28T00:00:002014Stimulation of the B-cell receptor activates the JAK2/STAT3 signaling pathway in chronic lymphocytic leukemia cells.24829205Wodarz D, Garg N, Komarova NL, Benjamini O, Keating MJ, Wierda WG, Kantarjian H, James D, O'Brien S, Burger JABloodKinetics of CLL cells in tissues and blood during therapy with the BTK inhibitor ibrutinib. Blood. 2014 Jun 26; 123(26):4132-5.Blood2014-05-14T00:00:002014Kinetics of CLL cells in tissues and blood during therapy with the BTK inhibitor ibrutinib.Authorship 2663982Authorship 2674971Authorship 2689377Authorship 26950317Authorship 2697883Authorship 26988911Authorship 2703418Authorship 2710331Authorship 2714771Authorship 2717609Authorship 2719821Authorship 272070815009064Zeiser R, Burger JA, Bley TA, Windfuhr-Blum M, Schulte-M?nting J, Behringer DMBritish journal of haematologyClinical follow-up indicates differential accuracy of magnetic resonance imaging and immunocytology of the cerebral spinal fluid for the diagnosis of neoplastic meningitis - a single centre experience. Br J Haematol. 2004 Mar; 124(6):762-8.Br J Haematol2004-03-01T00:00:002004Clinical follow-up indicates differential accuracy of magnetic resonance imaging and immunocytology of the cerebral spinal fluid for the diagnosis of neoplastic meningitis - a single centre experience.16888090Spoo AC, L?bbert M, Wierda WG, Burger JABloodCXCR4 is a prognostic marker in acute myelogenous leukemia. Blood. 2007 Jan 15; 109(2):786-91.Blood2006-08-03T00:00:002006CXCR4 is a prognostic marker in acute myelogenous leukemia.17456052Burger JA, B?rkle ABritish journal of haematologyThe CXCR4 chemokine receptor in acute and chronic leukaemia: a marrow homing receptor and potential therapeutic target. Br J Haematol. 2007 May; 137(4):288-96.Br J Haematol2007-05-01T00:00:002007The CXCR4 chemokine receptor in acute and chronic leukaemia: a marrow homing receptor and potential therapeutic target.19567878Jabbour E, Jones D, Kantarjian HM, O'Brien S, Tam C, Koller C, Burger JA, Borthakur G, Wierda WG, Cortes JBloodLong-term outcome of patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutations. Blood. 2009 Sep 03; 114(10):2037-43.Blood2009-06-30T00:00:002009Long-term outcome of patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutations.21115978Sivina M, Hartmann E, Kipps TJ, Rassenti L, Krupnik D, Lerner S, LaPushin R, Xiao L, Huang X, Werner L, Neuberg D, Kantarjian H, O'Brien S, Wierda WG, Keating MJ, Rosenwald A, Burger JABloodCCL3 (MIP-1a) plasma levels and the risk for disease progression in chronic lymphocytic leukemia. Blood. 2011 Feb 03; 117(5):1662-9.Blood2010-11-29T00:00:002010CCL3 (MIP-1a) plasma levels and the risk for disease progression in chronic lymphocytic leukemia.21725050Badoux XC, Keating MJ, Wen S, Lee BN, Sivina M, Reuben J, Wierda WG, O'Brien SM, Faderl S, Kornblau SM, Burger JA, Ferrajoli ABloodLenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia. Blood. 2011 Sep 29; 118(13):3489-98.Blood2011-07-01T00:00:002011Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia.22344033Zhang W, Trachootham D, Liu J, Chen G, Pelicano H, Garcia-Prieto C, Lu W, Burger JA, Croce CM, Plunkett W, Keating MJ, Huang PNature cell biologyStromal control of cystine metabolism promotes cancer cell survival in chronic lymphocytic leukaemia. Nat Cell Biol. 2012 Feb 19; 14(3):276-86.Nat Cell Biol2012-02-19T00:00:002012Stromal control of cystine metabolism promotes cancer cell survival in chronic lymphocytic leukaemia.23425038Burger JA, Buggy JJLeukemia & lymphomaBruton tyrosine kinase inhibitor ibrutinib (PCI-32765). Leuk Lymphoma. 2013 Nov; 54(11):2385-91.Leuk Lymphoma2013-08-28T00:00:002013Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765).23836561Ravandi F, Jorgensen JL, Thomas DA, O'Brien S, Garris R, Faderl S, Huang X, Wen S, Burger JA, Ferrajoli A, Kebriaei P, Champlin RE, Estrov Z, Challagundla P, Wang SA, Luthra R, Cortes JE, Kantarjian HMBloodDetection of MRD may predict the outcome of patients with Philadelphia chromosome-positive ALL treated with tyrosine kinase inhibitors plus chemotherapy. Blood. 2013 Aug 15; 122(7):1214-21.Blood2013-07-08T00:00:002013Detection of MRD may predict the outcome of patients with Philadelphia chromosome-positive ALL treated with tyrosine kinase inhibitors plus chemotherapy.24018164Burger JA, Gribben JGSeminars in cancer biologyThe microenvironment in chronic lymphocytic leukemia (CLL) and other B cell malignancies: insight into disease biology and new targeted therapies. Semin Cancer Biol. 2014 Feb; 24:71-81.Semin Cancer Biol2013-09-07T00:00:002013The microenvironment in chronic lymphocytic leukemia (CLL) and other B cell malignancies: insight into disease biology and new targeted therapies.24277076Hoellenriegel J, Zboralski D, Maasch C, Rosin NY, Wierda WG, Keating MJ, Kruschinski A, Burger JABloodThe Spiegelmer NOX-A12, a novel CXCL12 inhibitor, interferes with chronic lymphocytic leukemia cell motility and causes chemosensitization. Blood. 2014 Feb 13; 123(7):1032-9.Blood2013-11-25T00:00:002013The Spiegelmer NOX-A12, a novel CXCL12 inhibitor, interferes with chronic lymphocytic leukemia cell motility and causes chemosensitization.24642682Burger JA, Okkenhaug KNature reviews. Clinical oncologyHaematological cancer: idelalisib-targeting PI3Kd in patients with B-cell malignancies. Nat Rev Clin Oncol. 2014 Apr; 11(4):184-6.Nat Rev Clin Oncol2014-03-18T00:00:002014Haematological cancer: idelalisib-targeting PI3Kd in patients with B-cell malignancies.Authorship 2745936Authorship 2746741Authorship 27516911Authorship 275340221733558Badoux X, Bueso-Ramos C, Harris D, Li P, Liu Z, Burger J, O'Brien S, Ferrajoli A, Keating MJ, Estrov ZHuman pathologyCross-talk between chronic lymphocytic leukemia cells and bone marrow endothelial cells: role of signal transducer and activator of transcription 3. Hum Pathol. 2011 Dec; 42(12):1989-2000.Hum Pathol2011-07-05T00:00:002011Cross-talk between chronic lymphocytic leukemia cells and bone marrow endothelial cells: role of signal transducer and activator of transcription 3.22006556Burger JA, Hoellenriegel JOncotargetPhosphoinositide 3'-kinase delta: turning off BCR signaling in Chronic Lymphocytic Leukemia.. Oncotarget. 2011 Oct; 2(10):737-8.Oncotarget2011-10-01T00:00:002011Phosphoinositide 3'-kinase delta: turning off BCR signaling in Chronic Lymphocytic Leukemia..23725032Rozovski U, Calin GA, Setoyama T, D'Abundo L, Harris DM, Li P, Liu Z, Grgurevic S, Ferrajoli A, Faderl S, Burger JA, O'Brien S, Wierda WG, Keating MJ, Estrov ZMolecular cancerSignal transducer and activator of transcription (STAT)-3 regulates microRNA gene expression in chronic lymphocytic leukemia cells. Mol Cancer. 2013 Jun 01; 12:50.Mol Cancer2013-06-01T00:00:002013Signal transducer and activator of transcription (STAT)-3 regulates microRNA gene expression in chronic lymphocytic leukemia cells.24778403Ponader S, Burger JAJournal of clinical oncology : official journal of the American Society of Clinical OncologyBruton's tyrosine kinase: from X-linked agammaglobulinemia toward targeted therapy for B-cell malignancies. J Clin Oncol. 2014 Jun 10; 32(17):1830-9.J Clin Oncol2014-04-28T00:00:002014Bruton's tyrosine kinase: from X-linked agammaglobulinemia toward targeted therapy for B-cell malignancies.Authorship 2790615Authorship 2791134Authorship 2877491Authorship 28817415Authorship 2899925Authorship 2904856Authorship 2905002Authorship 2916452Authorship 2919852Authorship 2926692Authorship 2932826Authorship 29389010Authorship 2944218Authorship 29457519Authorship 2947015Authorship 2948455Authorship 2949229Authorship 2950777Authorship 29544210Authorship 29594628Authorship 2961733Authorship 2964094Authorship 2970767Authorship 2976097Authorship 2994066Authorship 2999012Authorship 29994823Authorship 3015212Authorship 30163034Authorship 302621124014291Burger JAAdvances in experimental medicine and biologyThe CLL cell microenvironment. Adv Exp Med Biol. 2013; 792:25-45.Adv Exp Med Biol2013-01-01T00:00:002013The CLL cell microenvironment.24376763Fiorcari S, Brown WS, McIntyre BW, Estrov Z, Maffei R, O'Brien S, Sivina M, Hoellenriegel J, Wierda WG, Keating MJ, Ding W, Kay NE, Lannutti BJ, Marasca R, Burger JAPloS oneThe PI3-kinase delta inhibitor idelalisib (GS-1101) targets integrin-mediated adhesion of chronic lymphocytic leukemia (CLL) cell to endothelial and marrow stromal cells. PLoS One. 2013; 8(12):e83830.PLoS One2013-12-23T00:00:002013The PI3-kinase delta inhibitor idelalisib (GS-1101) targets integrin-mediated adhesion of chronic lymphocytic leukemia (CLL) cell to endothelial and marrow stromal cells.24859876Strati P, Keating MJ, O'Brien SM, Ferrajoli A, Burger J, Faderl S, Tambaro FP, Jain N, Wierda WGHaematologicaOutcomes of first-line treatment for chronic lymphocytic leukemia with 17p deletion. Haematologica. 2014 Aug; 99(8):1350-5.Haematologica2014-05-23T00:00:002014Outcomes of first-line treatment for chronic lymphocytic leukemia with 17p deletion.25043749Jain P, Lee HJ, Qiao W, Wierda W, Benjamini O, Burger J, Ferrajoli A, Estrov Z, Kantarjian H, Keating M, O'Brien SCancerFCR and bevacizumab treatment in patients with relapsed chronic lymphocytic leukemia. Cancer. 2014 Nov 15; 120(22):3494-501.Cancer2014-07-15T00:00:002014FCR and bevacizumab treatment in patients with relapsed chronic lymphocytic leukemia.25050922ten Hacken E, Burger JAPharmacology & therapeuticsMicroenvironment dependency in Chronic Lymphocytic Leukemia: The basis for new targeted therapies. Pharmacol Ther. 2014 Dec; 144(3):338-48.Pharmacol Ther2014-07-19T00:00:002014Microenvironment dependency in Chronic Lymphocytic Leukemia: The basis for new targeted therapies.25201956Komarova NL, Burger JA, Wodarz DProceedings of the National Academy of Sciences of the United States of AmericaEvolution of ibrutinib resistance in chronic lymphocytic leukemia (CLL). Proc Natl Acad Sci U S A. 2014 Sep 23; 111(38):13906-11.Proc Natl Acad Sci U S A2014-09-08T00:00:002014Evolution of ibrutinib resistance in chronic lymphocytic leukemia (CLL).25387837Badar T, Burger JA, Wierda WG, O'Brien SExpert review of hematologyIbrutinib: a paradigm shift in management of CLL. Expert Rev Hematol. 2014 Dec; 7(6):705-17.Expert Rev Hematol2014-12-01T00:00:002014Ibrutinib: a paradigm shift in management of CLL.25499217Balakrishnan K, Burger JA, Fu M, Doifode T, Wierda WG, Gandhi VNeoplasia (New York, N.Y.)Regulation of Mcl-1 expression in context to bone marrow stromal microenvironment in chronic lymphocytic leukemia. Neoplasia. 2014 Dec; 16(12):1036-46.Neoplasia2014-12-01T00:00:002014Regulation of Mcl-1 expression in context to bone marrow stromal microenvironment in chronic lymphocytic leukemia.25522014Thompson PA, Ferrajoli A, O'Brien S, Wierda WG, Keating MJ, Burger JABritish journal of haematologyTrisomy 12 is associated with an abbreviated redistribution lymphocytosis during treatment with the BTK inhibitor ibrutinib in patients with chronic lymphocytic leukaemia. Br J Haematol. 2015 Jul; 170(1):125-8.Br J Haematol2014-12-18T00:00:002014Trisomy 12 is associated with an abbreviated redistribution lymphocytosis during treatment with the BTK inhibitor ibrutinib in patients with chronic lymphocytic leukaemia.25573991Jain P, Keating M, Wierda W, Estrov Z, Ferrajoli A, Jain N, George B, James D, Kantarjian H, Burger J, O'Brien SBloodOutcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib. Blood. 2015 Mar 26; 125(13):2062-7.Blood2015-01-08T00:00:002015Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib.25683856Jain P, Keating M, Thompson PA, Trinh L, Wang X, Wierda W, Ferrajoli A, Burger J, Kantarjian H, Estrov Z, Abruzzo L, O'Brien SAmerican journal of hematologyHigh fluorescence in situ hybridization percentage of deletion 11q in patients with chronic lymphocytic leukemia is an independent predictor of adverse outcome. Am J Hematol. 2015 Jun; 90(6):471-7.Am J Hematol2015-03-30T00:00:002015High fluorescence in situ hybridization percentage of deletion 11q in patients with chronic lymphocytic leukemia is an independent predictor of adverse outcome.25724525Daver N, Boumber Y, Kantarjian H, Ravandi F, Cortes J, Rytting ME, Kawedia JD, Basnett J, Culotta KS, Zeng Z, Lu H, Richie MA, Garris R, Xiao L, Liu W, Baggerly KA, Jabbour E, O'Brien S, Burger J, Bendall LJ, Thomas D, Konopleva MClinical cancer research : an official journal of the American Association for Cancer ResearchA Phase I/II Study of the mTOR Inhibitor Everolimus in Combination with HyperCVAD Chemotherapy in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia. Clin Cancer Res. 2015 Jun 15; 21(12):2704-14.Clin Cancer Res2015-02-27T00:00:002015A Phase I/II Study of the mTOR Inhibitor Everolimus in Combination with HyperCVAD Chemotherapy in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia.25733697Rozovski U, Grgurevic S, Bueso-Ramos C, Harris DM, Li P, Liu Z, Wu JY, Jain P, Wierda W, Burger J, O'Brien S, Jain N, Ferrajoli A, Keating MJ, Estrov ZMolecular cancer research : MCRAberrant LPL Expression, Driven by STAT3, Mediates Free Fatty Acid Metabolism in CLL Cells. Mol Cancer Res. 2015 May; 13(5):944-53.Mol Cancer Res2015-03-02T00:00:002015Aberrant LPL Expression, Driven by STAT3, Mediates Free Fatty Acid Metabolism in CLL Cells.25755291Brown JR, Barrientos JC, Barr PM, Flinn IW, Burger JA, Tran A, Clow F, James DF, Graef T, Friedberg JW, Rai K, O'Brien SBloodThe Bruton tyrosine kinase inhibitor ibrutinib with chemoimmunotherapy in patients with chronic lymphocytic leukemia. Blood. 2015 May 07; 125(19):2915-22.Blood2015-03-09T00:00:002015The Bruton tyrosine kinase inhibitor ibrutinib with chemoimmunotherapy in patients with chronic lymphocytic leukemia.25759025Geng H, Hurtz C, Lenz KB, Chen Z, Baumjohann D, Thompson S, Goloviznina NA, Chen WY, Huan J, LaTocha D, Ballabio E, Xiao G, Lee JW, Deucher A, Qi Z, Park E, Huang C, Nahar R, Kweon SM, Shojaee S, Chan LN, Yu J, Kornblau SM, Bijl JJ, Ye BH, Ansel KM, Paietta E, Melnick A, Hunger SP, Kurre P, Tyner JW, Loh ML, Roeder RG, Druker BJ, Burger JA, Milne TA, Chang BH, M?schen MCancer cellSelf-enforcing feedback activation between BCL6 and pre-B cell receptor signaling defines a distinct subtype of acute lymphoblastic leukemia. Cancer Cell. 2015 Mar 09; 27(3):409-25.Cancer Cell2015-03-09T00:00:002015Self-enforcing feedback activation between BCL6 and pre-B cell receptor signaling defines a distinct subtype of acute lymphoblastic leukemia.25795921Daver N, Cortes J, Ravandi F, Patel KP, Burger JA, Konopleva M, Kantarjian HBloodSecondary mutations as mediators of resistance to targeted therapy in leukemia. Blood. 2015 May 21; 125(21):3236-45.Blood2015-03-20T00:00:002015Secondary mutations as mediators of resistance to targeted therapy in leukemia.25809968Kadia TM, Faderl S, Ravandi F, Jabbour E, Garcia-Manero G, Borthakur G, Ferrajoli A, Konopleva M, Burger J, Huang X, Wang X, Pierce S, Brandt M, Feliu J, Cortes J, Kantarjian HCancerFinal results of a phase 2 trial of clofarabine and low-dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemia. Cancer. 2015 Jul 15; 121(14):2375-82.Cancer2015-03-25T00:00:002015Final results of a phase 2 trial of clofarabine and low-dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemia.25817936Sanford DS, Wierda WG, Burger JA, Keating MJ, O'Brien SMClinical lymphoma, myeloma & leukemiaThree newly approved drugs for chronic lymphocytic leukemia: incorporating ibrutinib, idelalisib, and obinutuzumab into clinical practice. Clin Lymphoma Myeloma Leuk. 2015 Jul; 15(7):385-91.Clin Lymphoma Myeloma Leuk2015-02-19T00:00:002015Three newly approved drugs for chronic lymphocytic leukemia: incorporating ibrutinib, idelalisib, and obinutuzumab into clinical practice.25847930Rozovski U, Benjamini O, Jain P, Thompson PA, Wierda WG, O'Brien S, Burger JA, Ferrajoli A, Faderl S, Shpall E, Hosing C, Khouri IF, Champlin R, Keating MJ, Estrov ZJournal of clinical oncology : official journal of the American Society of Clinical OncologyOutcomes of Patients With Chronic Lymphocytic Leukemia and Richter's Transformation After Transplantation Failure. J Clin Oncol. 2015 May 10; 33(14):1557-63.J Clin Oncol2015-04-06T00:00:002015Outcomes of Patients With Chronic Lymphocytic Leukemia and Richter's Transformation After Transplantation Failure.26193999Thompson PA, O'Brien SM, Wierda WG, Ferrajoli A, Stingo F, Smith SC, Burger JA, Estrov Z, Jain N, Kantarjian HM, Keating MJCancerComplex karyotype is a stronger predictor than del(17p) for an inferior outcome in relapsed or refractory chronic lymphocytic leukemia patients treated with ibrutinib-based regimens. Cancer. 2015 Oct 15; 121(20):3612-21.Cancer2015-07-20T00:00:002015Complex karyotype is a stronger predictor than del(17p) for an inferior outcome in relapsed or refractory chronic lymphocytic leukemia patients treated with ibrutinib-based regimens.26217876Yilmaz M, Lahoti A, O'Brien S, Nogueras-Gonz?lez GM, Burger J, Ferrajoli A, Borthakur G, Ravandi F, Pierce S, Jabbour E, Kantarjian H, Cortes JECancerEstimated glomerular filtration rate changes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. Cancer. 2015 Nov 01; 121(21):3894-904.Cancer2015-07-28T00:00:002015Estimated glomerular filtration rate changes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors.26308885Ravandi F, O'Brien SM, Cortes JE, Thomas DM, Garris R, Faderl S, Burger JA, Rytting ME, Ferrajoli A, Wierda WG, Verstovsek S, Champlin R, Kebriaei P, McCue DA, Huang X, Jabbour E, Garcia-Manero G, Estrov Z, Kantarjian HMCancerLong-term follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Cancer. 2015 Dec 01; 121(23):4158-64.Cancer2015-08-26T00:00:002015Long-term follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.26350103Okkenhaug K, Burger JACurrent topics in microbiology and immunologyPI3K Signaling in Normal B Cells and Chronic Lymphocytic Leukemia (CLL). Curr Top Microbiol Immunol. 2016; 393:123-142.Curr Top Microbiol Immunol2016-01-01T00:00:002016PI3K Signaling in Normal B Cells and Chronic Lymphocytic Leukemia (CLL).26358140Takahashi K, Sivina M, Hoellenriegel J, Oki Y, Hagemeister FB, Fayad L, Romaguera JE, Fowler N, Fanale MA, Kwak LW, Samaniego F, Neelapu S, Xiao L, Huang X, Kantarjian H, Keating MJ, Wierda W, Fu K, Chan WC, Vose JM, O'Brien S, Davis RE, Burger JABritish journal of haematologyCCL3 and CCL4 are biomarkers for B cell receptor pathway activation and prognostic serum markers in diffuse large B cell lymphoma. Br J Haematol. 2015 Dec; 171(5):726-35.Br J Haematol2015-09-11T00:00:002015CCL3 and CCL4 are biomarkers for B cell receptor pathway activation and prognostic serum markers in diffuse large B cell lymphoma.26472751O'Brien SM, Lamanna N, Kipps TJ, Flinn I, Zelenetz AD, Burger JA, Keating M, Mitra S, Holes L, Yu AS, Johnson DM, Miller LL, Kim Y, Dansey RD, Dubowy RL, Coutre SEBloodA phase 2 study of idelalisib plus rituximab in treatment-na?ve older patients with chronic lymphocytic leukemia. Blood. 2015 Dec 17; 126(25):2686-94.Blood2015-10-15T00:00:002015A phase 2 study of idelalisib plus rituximab in treatment-na?ve older patients with chronic lymphocytic leukemia.26614899Sivina M, Burger JABest practice & research. Clinical haematologyThe importance of the tissue microenvironment in hairy cell leukemia. Best Pract Res Clin Haematol. 2015 Dec; 28(4):208-16.Best Pract Res Clin Haematol2015-10-09T00:00:002015The importance of the tissue microenvironment in hairy cell leukemia.26639149Burger JA, Tedeschi A, Barr PM, Robak T, Owen C, Ghia P, Bairey O, Hillmen P, Bartlett NL, Li J, Simpson D, Grosicki S, Devereux S, McCarthy H, Coutre S, Quach H, Gaidano G, Maslyak Z, Stevens DA, Janssens A, Offner F, Mayer J, O'Dwyer M, Hellmann A, Schuh A, Siddiqi T, Polliack A, Tam CS, Suri D, Cheng M, Clow F, Styles L, James DF, Kipps TJ, RESONATE-2 InvestigatorsThe New England journal of medicineIbrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia. N Engl J Med. 2015 Dec 17; 373(25):2425-37.N Engl J Med2015-12-06T00:00:002015Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.26744434Burger JABloodObinutuzumab: the more the merrier? Blood. 2016 Jan 07; 127(1):6-8.Blood2016-01-07T00:00:002016Obinutuzumab: the more the merrier?74Professor10Assistant Professor14Associate Professor26492205Ravandi F, Jorgensen JL, O'Brien SM, Jabbour E, Thomas DA, Borthakur G, Garris R, Huang X, Garcia-Manero G, Burger JA, Ferrajoli A, Wierda W, Kadia T, Jain N, Wang SA, Konoplev S, Kebriaei P, Champlin RE, McCue D, Estrov Z, Cortes JE, Kantarjian HMBritish journal of haematologyMinimal residual disease assessed by multi-parameter flow cytometry is highly prognostic in adult patients with acute lymphoblastic leukaemia. Br J Haematol. 2016 Feb; 172(3):392-400.Br J Haematol2015-10-22T00:00:002015Minimal residual disease assessed by multi-parameter flow cytometry is highly prognostic in adult patients with acute lymphoblastic leukaemia.26733610Vitale C, Falchi L, Ten Hacken E, Gao H, Shaim H, Van Roosbroeck K, Calin G, O'Brien S, Faderl S, Wang X, Wierda WG, Rezvani K, Reuben JM, Burger JA, Keating MJ, Ferrajoli AClinical cancer research : an official journal of the American Association for Cancer ResearchOfatumumab and Lenalidomide for Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia: Correlation between Responses and Immune Characteristics. Clin Cancer Res. 2016 05 15; 22(10):2359-67.Clin Cancer Res2016-01-05T00:00:002016Ofatumumab and Lenalidomide for Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia: Correlation between Responses and Immune Characteristics.27199251Burger JA, Landau DA, Taylor-Weiner A, Bozic I, Zhang H, Sarosiek K, Wang L, Stewart C, Fan J, Hoellenriegel J, Sivina M, Dubuc AM, Fraser C, Han Y, Li S, Livak KJ, Zou L, Wan Y, Konoplev S, Sougnez C, Brown JR, Abruzzo LV, Carter SL, Keating MJ, Davids MS, Wierda WG, Cibulskis K, Zenz T, Werner L, Dal Cin P, Kharchencko P, Neuberg D, Kantarjian H, Lander E, Gabriel S, O'Brien S, Letai A, Weitz DA, Nowak MA, Getz G, Wu CJNature communicationsClonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition. Nat Commun. 2016 05 20; 7:11589.Nat Commun2016-05-20T00:00:002016Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition.21512135Manshouri T, Estrov Z, Quint?s-Cardama A, Burger J, Zhang Y, Livun A, Knez L, Harris D, Creighton CJ, Kantarjian HM, Verstovsek SCancer researchBone marrow stroma-secreted cytokines protect JAK2(V617F)-mutated cells from the effects of a JAK2 inhibitor. Cancer Res. 2011 Jun 01; 71(11):3831-40.Cancer Res2011-04-21T00:00:002011Bone marrow stroma-secreted cytokines protect JAK2(V617F)-mutated cells from the effects of a JAK2 inhibitor.Authorship 841741Authorship 841833Authorship 842080Authorship 842654Authorship 843421Authorship 843578Authorship 844031Authorship 844053Authorship 845203Authorship 846701Authorship 846749Authorship 846965Authorship 847325Authorship 847448Authorship 847620Authorship 848202Authorship 848620Authorship 849028Authorship 849336Authorship 849652Authorship 850386Authorship 850777Authorship 851585Authorship 851616Authorship 853209Authorship 853341Authorship 853952Authorship 857364Authorship 857380Authorship 858083Authorship 858811Authorship 859020Authorship 859385Authorship 859673Authorship 859916Authorship 860631Authorship 862538Authorship 862697Authorship 863529Authorship 863539Authorship 863932Authorship 864194Authorship 864431Authorship 864976Authorship 865411Authorship 865590Authorship 866139Authorship 866239Authorship 867405Authorship 867947Clinical Lymphoma, Myeloma and LeukemiaThree Newly Approved Drugs for Chronic Lymphocytic Leukemia. Clinical Lymphoma, Myeloma and Leukemia. Three Newly Approved Drugs for Chronic Lymphocytic LeukemiaThe Lancet HaematologyRuxolitinib for symptom control in patients with chronic lymphocytic leukaemia. The Lancet Haematology. Ruxolitinib for symptom control in patients with chronic lymphocytic leukaemiaNature CommunicationsClonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition. Nature Communications. 7.Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibitionTargeting CXCR4 in chronic lymphocytic leukemia. 369-385.Targeting CXCR4 in chronic lymphocytic leukemiaCurrent Topics in Microbiology and ImmunologyPI3K signaling in normal B cells and chronic lymphocytic leukemia (CLL). Current Topics in Microbiology and Immunology. 393:123-142.PI3K signaling in normal B cells and chronic lymphocytic leukemia (CLL)Open Hematology JournalCell trafficking in chronic lymphocytic leukemia. Open Hematology Journal. 3.Cell trafficking in chronic lymphocytic leukemiaClinical Advances in Hematology and OncologyB-cell receptor signaling in chronic lymphocytic leukemia and other B-cell malignancies. Clinical Advances in Hematology and Oncology. 14:55-65.B-cell receptor signaling in chronic lymphocytic leukemia and other B-cell malignanciesBloodFledgling prognostic markers in CLL. Blood. 110:3820-3821.Fledgling prognostic markers in CLLLeukemia and LymphomaSecond cancers in patients with chronic lymphocytic leukemia who received frontline fludarabine, cyclophosphamide and rituximab therapy. Leukemia and Lymphoma. 56:1643-1650.Second cancers in patients with chronic lymphocytic leukemia who received frontline fludarabine, cyclophosphamide and rituximab therapyLeukemiaOutcomes for patients with chronic lymphocytic leukemia and acute leukemia or myelodysplastic syndrome. Leukemia. 30:325-330.Outcomes for patients with chronic lymphocytic leukemia and acute leukemia or myelodysplastic syndromeBritish Journal of HaematologyCCL3 and CCL4 are biomarkers for B cell receptor pathway activation and prognostic serum markers in diffuse large B cell lymphoma. British Journal of Haematology. 171:726-735.CCL3 and CCL4 are biomarkers for B cell receptor pathway activation and prognostic serum markers in diffuse large B cell lymphomaBiochimica et Biophysica Acta - Molecular Cell ResearchMicroenvironment interactions and B-cell receptor signaling in Chronic Lymphocytic Leukemia. Biochimica et Biophysica Acta - Molecular Cell Research. Microenvironment interactions and B-cell receptor signaling in Chronic Lymphocytic LeukemiaBritish Journal of HaematologyEffects of pharmacological and genetic disruption of CXCR4 chemokine receptor function in B-cell acute lymphoblastic leukaemia. British Journal of Haematology. Effects of pharmacological and genetic disruption of CXCR4 chemokine receptor function in B-cell acute lymphoblastic leukaemiaThe microenvironment in chronic lymphocytic leukemia. 56-71.The microenvironment in chronic lymphocytic leukemiaCancer DiscoveryIbrutinib Is effective in relapsed CLL. Cancer Discovery. 3.Ibrutinib Is effective in relapsed CLLBritish Journal of HaematologyMinimal residual disease assessed by multi-parameter flow cytometry is highly prognostic in adult patients with acute lymphoblastic leukaemia. British Journal of Haematology. Minimal residual disease assessed by multi-parameter flow cytometry is highly prognostic in adult patients with acute lymphoblastic leukaemiaAmerican Journal of HematologyClinical and molecular characteristics of XPO1 mutations in patients with chronic lymphocytic leukemia. American Journal of Hematology. 91:E478-E479.Clinical and molecular characteristics of XPO1 mutations in patients with chronic lymphocytic leukemiaThe CLL cell microenvironment. 25-45.The CLL cell microenvironmentAmerican Journal of HematologyPrognostic impact of persistent cytogenetic abnormalities at complete remission in adult patients with acute lymphoblastic leukemia. American Journal of Hematology. Prognostic impact of persistent cytogenetic abnormalities at complete remission in adult patients with acute lymphoblastic leukemiaClinical Cancer ResearchOfatumumab and lenalidomide for patients with relapsed or refractory chronic lymphocytic leukemia. Clinical Cancer Research. 22:2359-2367.Ofatumumab and lenalidomide for patients with relapsed or refractory chronic lymphocytic leukemiaCancerEstimated glomerular filtration rate changes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. Cancer. Estimated glomerular filtration rate changes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitorsBest Practice and Research: Clinical HaematologyThe importance of the tissue microenvironment in hairy cell leukemia. Best Practice and Research: Clinical Haematology. 28:208-216.The importance of the tissue microenvironment in hairy cell leukemiaJournal of ImmunologyFunctional differences between IgM and IgD signaling in chronic lymphocytic leukemia. Journal of Immunology. 197:2522-2531.Functional differences between IgM and IgD signaling in chronic lymphocytic leukemiaCancer CellSelf-Enforcing Feedback Activation between BCL6 and Pre-B Cell Receptor Signaling Defines a Distinct Subtype of Acute Lymphoblastic Leukemia. Cancer Cell. 27:409-425.Self-Enforcing Feedback Activation between BCL6 and Pre-B Cell Receptor Signaling Defines a Distinct Subtype of Acute Lymphoblastic LeukemiaAmerican Journal of HematologyBuparlisib, a PI3K inhibitor, demonstrates acceptable tolerability and preliminary activity in a phase I trial of patients with advanced leukemias. American Journal of Hematology. 92:7-11.Buparlisib, a PI3K inhibitor, demonstrates acceptable tolerability and preliminary activity in a phase I trial of patients with advanced leukemiasMolecular Cancer ResearchAberrant LPL expression, driven by STAT3, Mediates free fatty acid metabolism in cll cells. Molecular Cancer Research. 13:944-953.Aberrant LPL expression, driven by STAT3, Mediates free fatty acid metabolism in cll cellsExpert Opinion on PharmacotherapyChronic lymphocytic leukemia therapy. Expert Opinion on Pharmacotherapy. 1-13.Chronic lymphocytic leukemia therapyCancerβ<sub>2</sub>-microglobulin normalization within 6 months of ibrutinib-based treatment is associated with superior progression-free survival in patients with chronic lymphocytic leukemia. Cancer. 122:565-573.β<sub>2</sub>-microglobulin normalization within 6 months of ibrutinib-based treatment is associated with superior progression-free survival in patients with chronic lymphocytic leukemiaHematological neoplasia. 400-526.Hematological neoplasiaThe Lancet OncologyIbrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma. The Lancet Oncology. 15:48-58.Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphomaHaematologicaHaematologica. 101:e295-e298.HaematologicaBloodA phase 2 study of idelalisib plus rituximab in treatment-naïve older patients with chronic lymphocytic leukemia. Blood. 126:2686-2694.A phase 2 study of idelalisib plus rituximab in treatment-naïve older patients with chronic lymphocytic leukemiaHaematologicaAutoimmune cytopenias in patients with chronic lymphocytic leukemia treated with ibrutinib. Haematologica. 101:e254-e258.Autoimmune cytopenias in patients with chronic lymphocytic leukemia treated with ibrutinibBloodNurse-like cells that support leukemic B cell survival are highly effective antigen presenting cells. Blood. 96.Nurse-like cells that support leukemic B cell survival are highly effective antigen presenting cellsLeukemiaBTK inhibition results in impaired CXCR4 chemokine receptor surface expression, signaling and function in chronic lymphocytic leukemia. Leukemia. BTK inhibition results in impaired CXCR4 chemokine receptor surface expression, signaling and function in chronic lymphocytic leukemiaClinical Cancer ResearchBendamustine in B-cell malignancies. Clinical Cancer Research. 15:7456-7461.Bendamustine in B-cell malignanciesBritish Journal of HaematologyDynamic changes in CCL3 and CCL4 plasma concentrations in patients with chronic lymphocytic leukaemia managed with observation. British Journal of Haematology. Dynamic changes in CCL3 and CCL4 plasma concentrations in patients with chronic lymphocytic leukaemia managed with observationClinical Cancer ResearchA phase I/II study of the mTOR inhibitor everolimus in combination with hyperCVAD chemotherapy in patients with relapsed/refractory acute lymphoblastic leukemia. Clinical Cancer Research. 21:2704-2714.A phase I/II study of the mTOR inhibitor everolimus in combination with hyperCVAD chemotherapy in patients with relapsed/refractory acute lymphoblastic leukemiaLeukemiaPre-BCR signaling in precursor B-cell acute lymphoblastic leukemia regulates PI3K/AKT, FOXO1 and MYC, and can be targeted by SYK inhibition. Leukemia. Pre-BCR signaling in precursor B-cell acute lymphoblastic leukemia regulates PI3K/AKT, FOXO1 and MYC, and can be targeted by SYK inhibitionCancerFCR and bevacizumab treatment in patients with relapsed chronic lymphocytic leukemia. Cancer. 120:3494-3501.FCR and bevacizumab treatment in patients with relapsed chronic lymphocytic leukemiaLeukemia and LymphomaCCL3 chemokine expression by chronic lymphocytic leukemia cells orchestrates the composition of the microenvironment in lymph node infiltrates. Leukemia and Lymphoma. CCL3 chemokine expression by chronic lymphocytic leukemia cells orchestrates the composition of the microenvironment in lymph node infiltratesCancerLong-term follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Cancer. Long-term follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemiaBloodObinutuzumab. Blood. 127:6-8.ObinutuzumabBritish Journal of HaematologyThe addition of CD20 monoclonal antibodies to lenalidomide improves response rates and survival in relapsed/refractory patients with chronic lymphocytic leukaemia relative to lenalidomide monotherapy - the MD Anderson Cancer Center experience. British Journal of Haematology. 171:281-284.The addition of CD20 monoclonal antibodies to lenalidomide improves response rates and survival in relapsed/refractory patients with chronic lymphocytic leukaemia relative to lenalidomide monotherapy - the MD Anderson Cancer Center experienceSpecial diagnostics. 39-64.Special diagnosticsBone Marrow TransplantationBendamustine added to allogeneic conditioning improves long-term outcomes in patients with CLL. Bone Marrow Transplantation. 52:28-33.Bendamustine added to allogeneic conditioning improves long-term outcomes in patients with CLLBloodNurse-like cells that support survival of chronic lymphocytic leukemia cells are derived from blood monocytes. Blood. 96.Nurse-like cells that support survival of chronic lymphocytic leukemia cells are derived from blood monocytesCancerComplex karyotype is a stronger predictor than del(17p) for an inferior outcome in relapsed or refractory chronic lymphocytic leukemia patients treated with ibrutinib-based regimens. Cancer. 121:3612-3621.Complex karyotype is a stronger predictor than del(17p) for an inferior outcome in relapsed or refractory chronic lymphocytic leukemia patients treated with ibrutinib-based regimensOncotargetIbrutinib modifies the function of monocyte/macrophage population in chronic lymphocytic leukemia. Oncotarget. 7:65968-65981.Ibrutinib modifies the function of monocyte/macrophage population in chronic lymphocytic leukemiaThe bone marrow microenvironment and its impact in acute and chronic B cell malignancies. 35-45.The bone marrow microenvironment and its impact in acute and chronic B cell malignancies28397242Jones JA, Hillmen P, Coutre S, Tam C, Furman RR, Barr PM, Schuster SJ, Kipps TJ, Flinn IW, Jaeger U, Burger JA, Cheng M, Ninomoto J, James DF, Byrd JC, O'Brien SMBritish journal of haematologyUse of anticoagulants and antiplatelet in patients with chronic lymphocytic leukaemia treated with single-agent ibrutinib. Br J Haematol. 2017 07; 178(2):286-291.Br J Haematol2017-04-10T00:00:002017Use of anticoagulants and antiplatelet in patients with chronic lymphocytic leukaemia treated with single-agent ibrutinib.20823404Parikh SA, Bhusal Y, Faderl SH, Wierda WG, O'Brien S, Kantarjian H, Adachi JA, Burger JAJournal of clinical oncology : official journal of the American Society of Clinical OncologyThe great imitator: systemic nocardiosis mimicking Richter's transformation in relapsed chronic lymphocytic leukemia. J Clin Oncol. 2010 Dec 10; 28(35):e732-4.J Clin Oncol2010-09-07T00:00:002010The great imitator: systemic nocardiosis mimicking Richter's transformation in relapsed chronic lymphocytic leukemia.Authorship 88726114Authorship 8884171Authorship 89019411Authorship 89027010D000225Chemicals & Drugs1956300.771226AdenineD011720Chemicals & Drugs46814710.521665PyrazolesD011743Chemicals & Drugs69735150.400272PyrimidinesAuthorship 9000072Authorship 9014422Authorship 90383810Authorship 9043616Authorship 90525313Authorship 9055085Authorship 9056081Authorship 9059915Authorship 9060988Authorship 9064171Authorship 9073002Authorship 9073245Authorship 90888810Authorship 9091632Authorship 9093102Authorship 90955510Authorship 9101562Authorship 91103013Authorship 9111999Authorship 91162418Authorship 9118911Authorship 9119516Authorship 91262010Authorship 91272310Authorship 9130193Authorship 91304618Authorship 9130761Authorship 9130912Authorship 9139733Authorship 91478013Authorship 9151982Authorship 9152897Authorship 9153149Authorship 9156205Authorship 9156477Authorship 91718014Authorship 91768910Authorship 91846311Authorship 91876815Authorship 9187942Authorship 9192662Authorship 92024910Authorship 9209507Authorship 9220588Authorship 9220878Authorship 9224748Authorship 92250112Authorship 92299110Authorship 9241048Authorship 9253904Authorship 9255571Authorship 92568116Authorship 9260928Authorship 92625122Authorship 9263398Authorship 92693511Authorship 9271929Authorship 92740720Authorship 92822111Authorship 92847521Authorship 9293121Authorship 9298131Authorship 93003817Authorship 93004921Authorship 9310222Authorship 93111714Authorship 9312228Authorship 9315405Authorship 9316662Authorship 93169519Authorship 93226825Authorship 9325378Authorship 9327007Authorship 9331475Authorship 9344007D011947Chemicals & Drugs771710.874112Receptors, Antigen, B-CellAuthorship 9346617Authorship 93488712Authorship 9350391Authorship 9358544Authorship 93681910Authorship 9376647Authorship 93777210Authorship 9383303Authorship 9388358Authorship 9393209Authorship 9395688Authorship 940281119996200Gandhi V, Burger JAClinical cancer research : an official journal of the American Association for Cancer ResearchBendamustine in B-Cell Malignancies: The New 46-Year-Old Kid on the Block. Clin Cancer Res. 2009 Dec 15; 15(24):7456-7461.Clin Cancer Res2009-12-15T00:00:002009Bendamustine in B-Cell Malignancies: The New 46-Year-Old Kid on the Block.22844583Davids MS, Burger JAOpen journal of hematologyCell Trafficking in Chronic Lymphocytic Leukemia. Open J Hematol. 2012; 3(S1).Open J Hematol2012-02-21T00:00:002012Cell Trafficking in Chronic Lymphocytic Leukemia.25824652Thompson PA, Rozovski U, Keating MJ, Stingo F, Smith SC, Wierda WG, Falchi L, O'Brien SM, Estrov Z, Burger JA, Ferrajoli ABritish journal of haematologyThe addition of CD20 monoclonal antibodies to lenalidomide improves response rates and survival in relapsed/refractory patients with chronic lymphocytic leukaemia relative to lenalidomide monotherapy - the MD Anderson Cancer Center experience. Br J Haematol. 2015 Oct; 171(2):281-284.Br J Haematol2015-03-30T00:00:002015The addition of CD20 monoclonal antibodies to lenalidomide improves response rates and survival in relapsed/refractory patients with chronic lymphocytic leukaemia relative to lenalidomide monotherapy - the MD Anderson Cancer Center experience.26193078Ten Hacken E, Burger JABiochimica et biophysica actaMicroenvironment interactions and B-cell receptor signaling in Chronic Lymphocytic Leukemia: Implications for disease pathogenesis and treatment. Biochim Biophys Acta. 2016 Mar; 1863(3):401-413.Biochim Biophys Acta2015-07-17T00:00:002015Microenvironment interactions and B-cell receptor signaling in Chronic Lymphocytic Leukemia: Implications for disease pathogenesis and treatment.26458057Hartmann EM, Rudelius M, Burger JA, Rosenwald ALeukemia & lymphomaCCL3 chemokine expression by chronic lymphocytic leukemia cells orchestrates the composition of the microenvironment in lymph node infiltrates. Leuk Lymphoma. 2016; 57(3):563-71.Leuk Lymphoma2015-10-12T00:00:002015CCL3 chemokine expression by chronic lymphocytic leukemia cells orchestrates the composition of the microenvironment in lymph node infiltrates.27013651Vitale C, Ahn IE, Sivina M, Ferrajoli A, Wierda WG, Estrov Z, Konoplev SN, Jain N, O'Brien S, Farooqui M, Keating MJ, Wiestner A, Burger JAHaematologicaAutoimmune cytopenias in patients with chronic lymphocytic leukemia treated with ibrutinib. Haematologica. 2016 06; 101(6):e254-8.Haematologica2016-03-24T00:00:002016Autoimmune cytopenias in patients with chronic lymphocytic leukemia treated with ibrutinib.27071778Randhawa S, Cho BS, Ghosh D, Sivina M, Koehrer S, M?schen M, Peled A, Davis RE, Konopleva M, Burger JABritish journal of haematologyEffects of pharmacological and genetic disruption of CXCR4 chemokine receptor function in B-cell acute lymphoblastic leukaemia. Br J Haematol. 2016 08; 174(3):425-36.Br J Haematol2016-04-12T00:00:002016Effects of pharmacological and genetic disruption of CXCR4 chemokine receptor function in B-cell acute lymphoblastic leukaemia.26588193Thompson PA, O'Brien SM, Xiao L, Wang X, Burger JA, Jain N, Ferrajoli A, Estrov Z, Keating MJ, Wierda WGCancer?2 -microglobulin normalization within 6 months of ibrutinib-based treatment is associated with superior progression-free survival in patients with chronic lymphocytic leukemia. Cancer. 2016 Feb 15; 122(4):565-73.Cancer2015-11-20T00:00:002015?2 -microglobulin normalization within 6 months of ibrutinib-based treatment is associated with superior progression-free survival in patients with chronic lymphocytic leukemia.26800008Short NJ, Kantarjian HM, Jabbour EJ, O'Brien SM, Faderl S, Burger JA, Garris R, Qiao W, Huang X, Jain N, Konopleva M, Kadia TM, Daver N, Borthakur G, Cortes JE, Ravandi FAmerican journal of hematologyPrognostic impact of persistent cytogenetic abnormalities at complete remission in adult patients with acute lymphoblastic leukemia. Am J Hematol. 2016 Jun; 91(4):385-9.Am J Hematol2016-02-09T00:00:002016Prognostic impact of persistent cytogenetic abnormalities at complete remission in adult patients with acute lymphoblastic leukemia.27096594Burger JA, Styles L, Kipps TJThe New England journal of medicineIbrutinib for Chronic Lymphocytic Leukemia. N Engl J Med. 2016 04 21; 374(16):1594-5.N Engl J Med2016-04-21T00:00:002016Ibrutinib for Chronic Lymphocytic Leukemia.27168204Burger JAClinical advances in hematology & oncology : H&OTargeted Agents for the Frontline Management of Chronic Lymphocytic Leukemia. Clin Adv Hematol Oncol. 2016 May; 14(5 Suppl 8):7-12.Clin Adv Hematol Oncol2016-05-01T00:00:002016Targeted Agents for the Frontline Management of Chronic Lymphocytic Leukemia.27168205Coutre SE, Burger JA, Pagel JMClinical advances in hematology & oncology : H&ODiscussion: Managing Risk When Using Idelalisib. Clin Adv Hematol Oncol. 2016 May; 14(5 Suppl 8):13.Clin Adv Hematol Oncol2016-05-01T00:00:002016Discussion: Managing Risk When Using Idelalisib.27301277Chihara D, Kantarjian H, O'Brien S, Jorgensen J, Pierce S, Faderl S, Ferrajoli A, Poku R, Jain P, Thompson P, Brandt M, Luthra R, Burger J, Keating M, Ravandi FBritish journal of haematologyLong-term durable remission by cladribine followed by rituximab in patients with hairy cell leukaemia: update of a phase II trial. Br J Haematol. 2016 Sep; 174(5):760-6.Br J Haematol2016-06-15T00:00:002016Long-term durable remission by cladribine followed by rituximab in patients with hairy cell leukaemia: update of a phase II trial.27151992Brown JR, Harb WA, Hill BT, Gabrilove J, Sharman JP, Schreeder MT, Barr PM, Foran JM, Miller TP, Burger JA, Kelly KR, Mahadevan D, Ma S, Li Y, Pierce DW, Barnett E, Marine J, Miranda M, Azaryan A, Yu X, Nava-Parada P, Mei J, Kipps TJHaematologicaPhase I study of single-agent CC-292, a highly selective Bruton's tyrosine kinase inhibitor, in relapsed/refractory chronic lymphocytic leukemia. Haematologica. 2016 07; 101(7):e295-8.Haematologica2016-05-05T00:00:002016Phase I study of single-agent CC-292, a highly selective Bruton's tyrosine kinase inhibitor, in relapsed/refractory chronic lymphocytic leukemia.27655665Jain N, Balakrishnan K, Ferrajoli A, O'Brien SM, Burger JA, Kadia TM, Cortes JE, Ayres ML, Tambaro FP, Keating MJ, Gandhi V, Wierda WGOncotargetA phase I-II trial of fludarabine, bendamustine and rituximab (FBR) in previously treated patients with CLL. Oncotarget. 2017 Mar 28; 8(13):22104-22112.Oncotarget2017-03-28T00:00:002017A phase I-II trial of fludarabine, bendamustine and rituximab (FBR) in previously treated patients with CLL.27057669Koehrer S, Burger JAClinical advances in hematology & oncology : H&OB-cell receptor signaling in chronic lymphocytic leukemia and other B-cell malignancies. Clin Adv Hematol Oncol. 2016 Jan; 14(1):55-65.Clin Adv Hematol Oncol2016-01-01T00:00:002016B-cell receptor signaling in chronic lymphocytic leukemia and other B-cell malignancies.26988407Vitale C, Burger JAExpert opinion on pharmacotherapyChronic lymphocytic leukemia therapy: new targeted therapies on the way. Expert Opin Pharmacother. 2016 Jun; 17(8):1077-89.Expert Opin Pharmacother2016-04-12T00:00:002016Chronic lymphocytic leukemia therapy: new targeted therapies on the way.27182988Thompson PA, Stingo F, Keating MJ, Ferrajoli A, Burger JA, Wierda WG, Kadia TM, O'Brien SMCancerOutcomes of patients with chronic lymphocytic leukemia treated with first-line idelalisib plus rituximab after cessation of treatment for toxicity. Cancer. 2016 08 15; 122(16):2505-11.Cancer2016-05-16T00:00:002016Outcomes of patients with chronic lymphocytic leukemia treated with first-line idelalisib plus rituximab after cessation of treatment for toxicity.27468087Jain P, Kanagal-Shamanna R, Wierda W, Keating M, Sarwari N, Rozovski U, Thompson P, Burger J, Kantarjian H, Patel KP, Medeiros LJ, Luthra R, Estrov ZAmerican journal of hematologyClinical and molecular characteristics of XPO1 mutations in patients with chronic lymphocytic leukemia. Am J Hematol. 2016 11; 91(11):E478-E479.Am J Hematol2016-08-22T00:00:002016Clinical and molecular characteristics of XPO1 mutations in patients with chronic lymphocytic leukemia.27742770Mathur R, Sehgal L, Havranek O, K?hrer S, Khashab T, Jain N, Burger JA, Neelapu SS, Davis RE, Samaniego FHaematologicaInhibition of demethylase KDM6B sensitizes diffuse large B-cell lymphoma to chemotherapeutic drugs. Haematologica. 2017 02; 102(2):373-380.Haematologica2016-10-14T00:00:002016Inhibition of demethylase KDM6B sensitizes diffuse large B-cell lymphoma to chemotherapeutic drugs.28073846Coutr? SE, Furman RR, Flinn IW, Burger JA, Blum K, Sharman J, Jones J, Wierda W, Zhao W, Heerema NA, Johnson AJ, Tran A, Zhou C, Bilotti E, James DF, Byrd JC, O'Brien SClinical cancer research : an official journal of the American Association for Cancer ResearchExtended Treatment with Single-Agent Ibrutinib at the 420 mg Dose Leads to Durable Responses in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. Clin Cancer Res. 2017 Mar 01; 23(5):1149-1155.Clin Cancer Res2017-01-10T00:00:002017Extended Treatment with Single-Agent Ibrutinib at the 420 mg Dose Leads to Durable Responses in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.28077600Yin Q, Sivina M, Robins H, Yusko E, Vignali M, O'Brien S, Keating MJ, Ferrajoli A, Estrov Z, Jain N, Wierda WG, Burger JAJournal of immunology (Baltimore, Md. : 1950)Ibrutinib Therapy Increases T Cell Repertoire Diversity in Patients with Chronic Lymphocytic Leukemia. J Immunol. 2017 02 15; 198(4):1740-1747.J Immunol2017-01-11T00:00:002017Ibrutinib Therapy Increases T Cell Repertoire Diversity in Patients with Chronic Lymphocytic Leukemia.28138560Burger JA, Li KW, Keating MJ, Sivina M, Amer AM, Garg N, Ferrajoli A, Huang X, Kantarjian H, Wierda WG, O'Brien S, Hellerstein MK, Turner SM, Emson CL, Chen SS, Yan XJ, Wodarz D, Chiorazzi NJCI insightLeukemia cell proliferation and death in chronic lymphocytic leukemia patients on therapy with the BTK inhibitor ibrutinib. JCI Insight. 2017 01 26; 2(2):e89904.JCI Insight2017-01-26T00:00:002017Leukemia cell proliferation and death in chronic lymphocytic leukemia patients on therapy with the BTK inhibitor ibrutinib.27797975Jain P, Keating MJ, Wierda WG, Sivina M, Thompson PA, Ferrajoli A, Estrov Z, Kantarjian H, O'Brien S, Burger JAClinical cancer research : an official journal of the American Association for Cancer ResearchLong-term Follow-up of Treatment with Ibrutinib and Rituximab in Patients with High-Risk Chronic Lymphocytic Leukemia. Clin Cancer Res. 2017 May 01; 23(9):2154-2158.Clin Cancer Res2016-10-19T00:00:002016Long-term Follow-up of Treatment with Ibrutinib and Rituximab in Patients with High-Risk Chronic Lymphocytic Leukemia.28130399Rozovski U, Harris DM, Li P, Liu Z, Jain P, Veletic I, Ferrajoli A, Burger J, O'Brien S, Bose P, Thompson P, Jain N, Wierda W, Keating MJ, Estrov ZMolecular cancer research : MCRConstitutive Phosphorylation of STAT3 by the CK2-BLNK-CD5 Complex. Mol Cancer Res. 2017 05; 15(5):610-618.Mol Cancer Res2017-01-27T00:00:002017Constitutive Phosphorylation of STAT3 by the CK2-BLNK-CD5 Complex.27697994Blunt MD, Koehrer S, Dobson RC, Larrayoz M, Wilmore S, Hayman A, Parnell J, Smith LD, Davies A, Johnson PWM, Conley PB, Pandey A, Strefford JC, Stevenson FK, Packham G, Forconi F, Coffey GP, Burger JA, Steele AJClinical cancer research : an official journal of the American Association for Cancer ResearchThe Dual Syk/JAK Inhibitor Cerdulatinib Antagonizes B-cell Receptor and Microenvironmental Signaling in Chronic Lymphocytic Leukemia. Clin Cancer Res. 2017 May 01; 23(9):2313-2324.Clin Cancer Res2016-10-03T00:00:002016The Dual Syk/JAK Inhibitor Cerdulatinib Antagonizes B-cell Receptor and Microenvironmental Signaling in Chronic Lymphocytic Leukemia.28031181Kim E, Hurtz C, Koehrer S, Wang Z, Balasubramanian S, Chang BY, M?schen M, Davis RE, Burger JABloodIbrutinib inhibits pre-BCR+ B-cell acute lymphoblastic leukemia progression by targeting BTK and BLK. Blood. 2017 03 02; 129(9):1155-1165.Blood2016-12-28T00:00:002016Ibrutinib inhibits pre-BCR+ B-cell acute lymphoblastic leukemia progression by targeting BTK and BLK.27534555Ten Hacken E, Sivina M, Kim E, O'Brien S, Wierda WG, Ferrajoli A, Estrov Z, Keating MJ, Oellerich T, Scielzo C, Ghia P, Caligaris-Cappio F, Burger JAJournal of immunology (Baltimore, Md. : 1950)Functional Differences between IgM and IgD Signaling in Chronic Lymphocytic Leukemia. J Immunol. 2016 09 15; 197(6):2522-31.J Immunol2016-08-17T00:00:002016Functional Differences between IgM and IgD Signaling in Chronic Lymphocytic Leukemia.27602755Fiorcari S, Maffei R, Audrito V, Martinelli S, Ten Hacken E, Zucchini P, Grisendi G, Potenza L, Luppi M, Burger JA, Deaglio S, Marasca ROncotargetIbrutinib modifies the function of monocyte/macrophage population in chronic lymphocytic leukemia. Oncotarget. 2016 Oct 04; 7(40):65968-65981.Oncotarget2016-10-04T00:00:002016Ibrutinib modifies the function of monocyte/macrophage population in chronic lymphocytic leukemia.27673440Ragon BK, Kantarjian H, Jabbour E, Ravandi F, Cortes J, Borthakur G, DeBose L, Zeng Z, Schneider H, Pemmaraju N, Garcia-Manero G, Kornblau S, Wierda W, Burger J, DiNardo CD, Andreeff M, Konopleva M, Daver NAmerican journal of hematologyBuparlisib, a PI3K inhibitor, demonstrates acceptable tolerability and preliminary activity in a phase I trial of patients with advanced leukemias. Am J Hematol. 2017 Jan; 92(1):7-11.Am J Hematol2016-12-07T00:00:002016Buparlisib, a PI3K inhibitor, demonstrates acceptable tolerability and preliminary activity in a phase I trial of patients with advanced leukemias.27766619Sivina M, Werner L, Rassenti L, Ferrajoli A, Wierda WG, Keating MJ, O'Brien S, Neuberg D, Kipps T, Burger JABritish journal of haematologyDynamic changes in CCL3 and CCL4 plasma concentrations in patients with chronic lymphocytic leukaemia managed with observation. Br J Haematol. 2018 02; 180(4):597-600.Br J Haematol2016-10-21T00:00:002016Dynamic changes in CCL3 and CCL4 plasma concentrations in patients with chronic lymphocytic leukaemia managed with observation.28089238Jain P, Keating M, Renner S, Cleeland C, Xuelin H, Gonzalez GN, Harris D, Li P, Liu Z, Veletic I, Rozovski U, Jain N, Thompson P, Bose P, DiNardo C, Ferrajoli A, O'Brien S, Burger J, Wierda W, Verstovsek S, Kantarjian H, Estrov ZThe Lancet. HaematologyRuxolitinib for symptom control in patients with chronic lymphocytic leukaemia: a single-group, phase 2 trial. Lancet Haematol. 2017 Feb; 4(2):e67-e74.Lancet Haematol2017-01-12T00:00:002017Ruxolitinib for symptom control in patients with chronic lymphocytic leukaemia: a single-group, phase 2 trial.28153836Ten Hacken E, Burger JABloodHSP90, a chaperone that can make you SYK. Blood. 2017 02 02; 129(5):542-544.Blood2017-02-02T00:00:002017HSP90, a chaperone that can make you SYK.28373262Barr PM, Brown JR, Hillmen P, O'Brien S, Barrientos JC, Reddy NM, Coutre S, Mulligan SP, Jaeger U, Furman RR, Cymbalista F, Montillo M, Dearden C, Robak T, Moreno C, Pagel JM, Burger JA, Suzuki S, Sukbuntherng J, Cole G, James DF, Byrd JCBloodImpact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLL. Blood. 2017 05 11; 129(19):2612-2615.Blood2017-04-03T00:00:002017Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLL.28670739Jain P, Burger JA, Khoury JDAmerican journal of hematologyCLL progression after one cycle of FCR: Richter's transformation versus EBV-associated lympho-proliferation. Am J Hematol. 2017 10; 92(10):1113-1114.Am J Hematol2017-08-10T00:00:002017CLL progression after one cycle of FCR: Richter's transformation versus EBV-associated lympho-proliferation.28722170Rozovski U, Harris DM, Li P, Liu Z, Jain P, Veletic I, Ferrajoli A, Burger J, Thompson P, Jain N, Wierda W, Keating MJ, Estrov ZInternational journal of cancerActivation of the B-cell receptor successively activates NF-?B and STAT3 in chronic lymphocytic leukemia cells. Int J Cancer. 2017 11 15; 141(10):2076-2081.Int J Cancer2017-08-04T00:00:002017Activation of the B-cell receptor successively activates NF-?B and STAT3 in chronic lymphocytic leukemia cells.28646116Havranek O, Xu J, K?hrer S, Wang Z, Becker L, Comer JM, Henderson J, Ma W, Man Chun Ma J, Westin JR, Ghosh D, Shinners N, Sun L, Yi AF, Karri AR, Burger JA, Zal T, Davis REBloodTonic B-cell receptor signaling in diffuse large B-cell lymphoma. Blood. 2017 08 24; 130(8):995-1006.Blood2017-06-23T00:00:002017Tonic B-cell receptor signaling in diffuse large B-cell lymphoma.28171709Jain P, Thompson PA, Keating M, Estrov Z, Ferrajoli A, Jain N, Kantarjian H, Burger JA, O'Brien S, Wierda WGCancerLong-term outcomes for patients with chronic lymphocytic leukemia who discontinue ibrutinib. Cancer. 2017 Jun 15; 123(12):2268-2273.Cancer2017-02-07T00:00:002017Long-term outcomes for patients with chronic lymphocytic leukemia who discontinue ibrutinib.28798068Strati P, Keating MJ, Burger JA, O'Brien SM, Wierda WG, Estrov Z, Zacharian G, Ferrajoli AHaematologicaConsolidation treatment with lenalidomide following front-line or salvage chemoimmunotherapy in chronic lymphocytic leukemia. Haematologica. 2017 12; 102(12):e494-e496.Haematologica2017-08-10T00:00:002017Consolidation treatment with lenalidomide following front-line or salvage chemoimmunotherapy in chronic lymphocytic leukemia.29125406Thompson PA, Burger JAExpert opinion on investigational drugsBruton's tyrosine kinase inhibitors: first and second generation agents for patients with Chronic Lymphocytic Leukemia (CLL). Expert Opin Investig Drugs. 2018 01; 27(1):31-42.Expert Opin Investig Drugs2017-11-15T00:00:002017Bruton's tyrosine kinase inhibitors: first and second generation agents for patients with Chronic Lymphocytic Leukemia (CLL).28927784Assi R, Kantarjian H, Short NJ, Daver N, Takahashi K, Garcia-Manero G, DiNardo C, Burger J, Cortes J, Jain N, Wierda W, Chamoun S, Konopleva M, Jabbour EClinical lymphoma, myeloma & leukemiaSafety and Efficacy of Blinatumomab in Combination With a Tyrosine Kinase Inhibitor for the Treatment of Relapsed Philadelphia Chromosome-positive Leukemia. Clin Lymphoma Myeloma Leuk. 2017 Dec; 17(12):897-901.Clin Lymphoma Myeloma Leuk2017-08-18T00:00:002017Safety and Efficacy of Blinatumomab in Combination With a Tyrosine Kinase Inhibitor for the Treatment of Relapsed Philadelphia Chromosome-positive Leukemia.28972430Boddu P, Shah AR, Borthakur G, Verstovsek S, Garcia-Manero G, Daver N, Kadia T, Ravandi F, Jain N, Alhuraiji A, Burger J, Kornblau S, Pierce S, Dellasala S, Jabbour E, Kantarjian H, Cortes JLeukemia & lymphomaLife after ponatinib failure: outcomes of chronic and accelerated phase CML patients who discontinued ponatinib in the salvage setting. Leuk Lymphoma. 2018 06; 59(6):1312-1322.Leuk Lymphoma2017-10-03T00:00:002017Life after ponatinib failure: outcomes of chronic and accelerated phase CML patients who discontinued ponatinib in the salvage setting.29047158Abaza Y, M Kantarjian H, Faderl S, Jabbour E, Jain N, Thomas D, Kadia T, Borthakur G, D Khoury J, Burger J, Wierda W, O'Brien S, Konopleva M, Ferrajoli A, Kebriaei P, Dabaja B, Kornblau S, Alvarado Y, Daver N, Pemmaraju N, Bose P, Thompson P, Al Azzawi H, Kelly M, Garris R, Jain P, Garcia-Manero G, Cortes J, Ravandi FAmerican journal of hematologyHyper-CVAD plus nelarabine in newly diagnosed adult T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphoma. Am J Hematol. 2018 01; 93(1):91-99.Am J Hematol2017-11-03T00:00:002017Hyper-CVAD plus nelarabine in newly diagnosed adult T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphoma.29164608Jain P, Nogueras Gonz?lez GM, Kanagal-Shamanna R, Rozovski U, Sarwari N, Tam C, Wierda WG, Thompson PA, Jain N, Luthra R, Quesada A, Sanchez-Petitto G, Ferrajoli A, Burger J, Kantarjian H, Cortes J, O'Brien S, Keating MJ, Estrov ZBritish journal of haematologyThe absolute percent deviation of IGHV mutation rather than a 98% cut-off predicts survival of chronic lymphocytic leukaemia patients treated with fludarabine, cyclophosphamide and rituximab. Br J Haematol. 2018 01; 180(1):33-40.Br J Haematol2017-11-21T00:00:002017The absolute percent deviation of IGHV mutation rather than a 98% cut-off predicts survival of chronic lymphocytic leukaemia patients treated with fludarabine, cyclophosphamide and rituximab.28751558Brown JR, Moslehi J, O'Brien S, Ghia P, Hillmen P, Cymbalista F, Shanafelt TD, Fraser G, Rule S, Kipps TJ, Coutre S, Dilhuydy MS, Cramer P, Tedeschi A, Jaeger U, Dreyling M, Byrd JC, Howes A, Todd M, Vermeulen J, James DF, Clow F, Styles L, Valentino R, Wildgust M, Mahler M, Burger JAHaematologicaCharacterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials. Haematologica. 2017 10; 102(10):1796-1805.Haematologica2017-07-27T00:00:002017Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials.28751563ten Hacken E, Gounari M, Back JW, Shimanovskaya E, Scarf? L, Kim E, Burks J, Ponzoni M, Ramirez GA, Wierda WG, Estrov Z, Keating MJ, Ferrajoli A, Stamatopoulos K, Ghia P, Burger JAHaematologicaCalreticulin as a novel B-cell receptor antigen in chronic lymphocytic leukemia. Haematologica. 2017 10; 102(10):e394-e396.Haematologica2017-07-27T00:00:002017Calreticulin as a novel B-cell receptor antigen in chronic lymphocytic leukemia.29191916Flinn IW, O'Brien S, Kahl B, Patel M, Oki Y, Foss FF, Porcu P, Jones J, Burger JA, Jain N, Kelly VM, Allen K, Douglas M, Sweeney J, Kelly P, Horwitz SBloodDuvelisib, a novel oral dual inhibitor of PI3K-d,?, is clinically active in advanced hematologic malignancies. Blood. 2018 02 22; 131(8):877-887.Blood2017-11-30T00:00:002017Duvelisib, a novel oral dual inhibitor of PI3K-d,?, is clinically active in advanced hematologic malignancies.29259203Landau DA, Sun C, Rosebrock D, Herman SEM, Fein J, Sivina M, Underbayev C, Liu D, Hoellenriegel J, Ravichandran S, Farooqui MZH, Zhang W, Cibulskis C, Zviran A, Neuberg DS, Livitz D, Bozic I, Leshchiner I, Getz G, Burger JA, Wiestner A, Wu CJNature communicationsThe evolutionary landscape of chronic lymphocytic leukemia treated with ibrutinib targeted therapy. Nat Commun. 2017 12 19; 8(1):2185.Nat Commun2017-12-19T00:00:002017The evolutionary landscape of chronic lymphocytic leukemia treated with ibrutinib targeted therapy.29465264Rozovski U, Harris DM, Li P, Liu Z, Jain P, Ferrajoli A, Burger J, Thompson P, Jain N, Wierda W, Keating MJ, Estrov ZLeukemia & lymphomaIbrutinib inhibits free fatty acid metabolism in chronic lymphocytic leukemia. Leuk Lymphoma. 2018 11; 59(11):2686-2691.Leuk Lymphoma2018-02-21T00:00:002018Ibrutinib inhibits free fatty acid metabolism in chronic lymphocytic leukemia.29479067Strati P, Ferrajoli A, Wierda WG, Jain N, Thompson PA, O'Brien SM, Rezvani K, Kantarjian HM, Burger JA, Hinojosa CO, Keating MJ, Estrov ZLeukemiaSustained long-lasting responses after lenalidomide discontinuation in patients with chronic lymphocytic leukemia. Leukemia. 2018 10; 32(10):2278-2281.Leukemia2018-02-20T00:00:002018Sustained long-lasting responses after lenalidomide discontinuation in patients with chronic lymphocytic leukemia.29301866Tissino E, Benedetti D, Herman SEM, Ten Hacken E, Ahn IE, Chaffee KG, Rossi FM, Dal Bo M, Bulian P, Bomben R, Bayer E, H?rzschel A, Gutjahr JC, Postorino M, Santinelli E, Ayed A, Zaja F, Chiarenza A, Pozzato G, Chigaev A, Sklar LA, Burger JA, Ferrajoli A, Shanafelt TD, Wiestner A, Del Poeta G, Hartmann TN, Gattei V, Zucchetto AThe Journal of experimental medicineFunctional and clinical relevance of VLA-4 (CD49d/CD29) in ibrutinib-treated chronic lymphocytic leukemia. J Exp Med. 2018 02 05; 215(2):681-697.J Exp Med2018-01-04T00:00:002018Functional and clinical relevance of VLA-4 (CD49d/CD29) in ibrutinib-treated chronic lymphocytic leukemia.29379494Shaim H, Estrov Z, Harris D, Hernandez Sanabria M, Liu Z, Ruvolo P, Thompson PA, Ferrajoli A, Daher M, Burger J, Muftuoglu M, Imahashi N, Li L, Liu E, Alsuliman AS, Basar R, Nassif Kerbauy L, Sobieski C, Gokdemir E, Kondo K, Wierda W, Keating M, Shpall EJ, Rezvani KFrontiers in immunologyThe CXCR4-STAT3-IL-10 Pathway Controls the Immunoregulatory Function of Chronic Lymphocytic Leukemia and Is Modulated by Lenalidomide. Front Immunol. 2017; 8:1773.Front Immunol2018-01-15T00:00:002018The CXCR4-STAT3-IL-10 Pathway Controls the Immunoregulatory Function of Chronic Lymphocytic Leukemia and Is Modulated by Lenalidomide.29358183Takahashi K, Hu B, Wang F, Yan Y, Kim E, Vitale C, Patel KP, Strati P, Gumbs C, Little L, Tippen S, Song X, Zhang J, Jain N, Thompson P, Garcia-Manero G, Kantarjian H, Estrov Z, Do KA, Keating M, Burger JA, Wierda WG, Futreal PA, Ferrajoli ABloodClinical implications of cancer gene mutations in patients with chronic lymphocytic leukemia treated with lenalidomide. Blood. 2018 04 19; 131(16):1820-1832.Blood2018-01-22T00:00:002018Clinical implications of cancer gene mutations in patients with chronic lymphocytic leukemia treated with lenalidomide.29437592O'Brien S, Furman RR, Coutre S, Flinn IW, Burger JA, Blum K, Sharman J, Wierda W, Jones J, Zhao W, Heerema NA, Johnson AJ, Luan Y, James DF, Chu AD, Byrd JCBloodSingle-agent ibrutinib in treatment-na?ve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience. Blood. 2018 04 26; 131(17):1910-1919.Blood2018-02-02T00:00:002018Single-agent ibrutinib in treatment-na?ve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience.29723397Naqvi K, Jabbour E, Skinner J, Yilmaz M, Ferrajoli A, Bose P, Thompson P, Alvarado Y, Jain N, Takahashi K, Burger J, Estrov Z, Borthakur G, Pemmaraju N, Paul S, Cortes J, Kantarjian HMCancerEarly results of lower dose dasatinib (50?mg daily) as frontline therapy for newly diagnosed chronic-phase chronic myeloid leukemia. Cancer. 2018 07 01; 124(13):2740-2747.Cancer2018-05-03T00:00:002018Early results of lower dose dasatinib (50?mg daily) as frontline therapy for newly diagnosed chronic-phase chronic myeloid leukemia.29724714Burger JABloodNew pieces in the BTKi resistance puzzle. Blood. 2018 05 03; 131(18):1995-1996.Blood2018-05-03T00:00:002018New pieces in the BTKi resistance puzzle.29210027Okkenhaug K, Burger JACurrent topics in microbiology and immunologyErratum to: PI3K Signaling in Normal B Cells and Chronic Lymphocytic Leukemia (CLL). Curr Top Microbiol Immunol. 2016; 393:E1.Curr Top Microbiol Immunol2016-01-01T00:00:002016Erratum to: PI3K Signaling in Normal B Cells and Chronic Lymphocytic Leukemia (CLL).29348577Burger JA, Wiestner ANature reviews. CancerTargeting B cell receptor signalling in cancer: preclinical and clinical advances. Nat Rev Cancer. 2018 03; 18(3):148-167.Nat Rev Cancer2018-01-19T00:00:002018Targeting B cell receptor signalling in cancer: preclinical and clinical advances.29352703Kantarjian H, Ravandi F, Short NJ, Huang X, Jain N, Sasaki K, Daver N, Pemmaraju N, Khoury JD, Jorgensen J, Alvarado Y, Konopleva M, Garcia-Manero G, Kadia T, Yilmaz M, Bortakhur G, Burger J, Kornblau S, Wierda W, DiNardo C, Ferrajoli A, Jacob J, Garris R, O'Brien S, Jabbour EThe Lancet. OncologyInotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study. Lancet Oncol. 2018 02; 19(2):240-248.Lancet Oncol2018-01-16T00:00:002018Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study.29632735Schliffke S, Sivina M, Kim E, von Wenserski L, Thiele B, Aky?z N, Falker-Gieske C, Statovci D, Oberle A, Thenhausen T, Krohn-Grimberghe A, Bokemeyer C, Jain N, Estrov Z, Ferrajoli A, Wierda W, Keating M, Burger JA, Binder MOncoimmunologyDynamic changes of the normal B lymphocyte repertoire in CLL in response to ibrutinib or FCR chemo-immunotherapy. Oncoimmunology. 2018; 7(4):e1417720.Oncoimmunology2018-01-15T00:00:002018Dynamic changes of the normal B lymphocyte repertoire in CLL in response to ibrutinib or FCR chemo-immunotherapy.30277101Barrientos JC, Burger JA, Byrd JC, Hillmen P, Zhou C, Ninomoto J, James DF, Kipps TJLeukemia & lymphomaCharacterizing the kinetics of lymphocytosis in patients with chronic lymphocytic leukemia treated with single-agent ibrutinib. Leuk Lymphoma. 2019 04; 60(4):1000-1005.Leuk Lymphoma2018-10-02T00:00:002018Characterizing the kinetics of lymphocytosis in patients with chronic lymphocytic leukemia treated with single-agent ibrutinib.30282833Ten Hacken E, Valentin R, Regis FFD, Sun J, Yin S, Werner L, Deng J, Gruber M, Wong J, Zheng M, Gill AL, Seiler M, Smith P, Thomas M, Buonamici S, Ghia EM, Kim E, Rassenti LZ, Burger JA, Kipps TJ, Meyerson ML, Bachireddy P, Wang L, Reed R, Neuberg D, Carrasco RD, Brooks AN, Letai A, Davids MS, Wu CJJCI insightSplicing modulation sensitizes chronic lymphocytic leukemia cells to venetoclax by remodeling mitochondrial apoptotic dependencies. JCI Insight. 2018 10 04; 3(19).JCI Insight2018-10-04T00:00:002018Splicing modulation sensitizes chronic lymphocytic leukemia cells to venetoclax by remodeling mitochondrial apoptotic dependencies.29903571Peled A, Klein S, Beider K, Burger JA, Abraham MCytokineRole of CXCL12 and CXCR4 in the pathogenesis of hematological malignancies. Cytokine. 2018 09; 109:11-16.Cytokine2018-09-01T00:00:002018Role of CXCL12 and CXCR4 in the pathogenesis of hematological malignancies.30061088O'Brien S, Hillmen P, Coutre S, Barr PM, Fraser G, Tedeschi A, Burger JA, Dilhuydy MS, Hess G, Moreno C, Cramer P, Liu E, Chang S, Vermeulen J, Styles L, Howes A, James DF, Patel K, Graef T, Valentino RClinical lymphoma, myeloma & leukemiaSafety Analysis of Four Randomized Controlled?Studies of Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Mantle Cell Lymphoma. Clin Lymphoma Myeloma Leuk. 2018 10; 18(10):648-657.e15.Clin Lymphoma Myeloma Leuk2018-06-28T00:00:002018Safety Analysis of Four Randomized Controlled?Studies of Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Mantle Cell Lymphoma.30129285Robak T, Burger JA, Tedeschi A, Barr PM, Owen C, Bairey O, Hillmen P, Simpson D, Grosicki S, Devereux S, McCarthy H, Coutre SE, Quach H, Gaidano G, Maslyak Z, Stevens DA, Moreno C, Gill DS, Flinn IW, Gribben JG, Mokatrin A, Cheng M, Styles L, James DF, Kipps TJ, Ghia PAmerican journal of hematologySingle-agent ibrutinib versus chemoimmunotherapy regimens for treatment-na?ve patients with chronic lymphocytic leukemia: A cross-trial comparison of phase 3 studies. Am J Hematol. 2018 11; 93(11):1402-1410.Am J Hematol2018-10-09T00:00:002018Single-agent ibrutinib versus chemoimmunotherapy regimens for treatment-na?ve patients with chronic lymphocytic leukemia: A cross-trial comparison of phase 3 studies.30263097Rozovski U, Harris DM, Li P, Liu Z, Jain P, Ferrajoli A, Burger J, Thompson P, Jain N, Wierda W, Keating MJ, Estrov ZOncotargetSTAT3 is constitutively acetylated on lysine 685 residues in chronic lymphocytic leukemia cells. Oncotarget. 2018 Sep 14; 9(72):33710-33718.Oncotarget2018-09-14T00:00:002018STAT3 is constitutively acetylated on lysine 685 residues in chronic lymphocytic leukemia cells.30406944Paul S, Jain N, Ferrajoli A, O'Brien S, Burger J, Keating M, Wierda WBritish journal of haematologyA phase II trial of eltrombopag for patients with chronic lymphocytic leukaemia (CLL) and thrombocytopenia. Br J Haematol. 2019 05; 185(3):606-608.Br J Haematol2018-11-08T00:00:002018A phase II trial of eltrombopag for patients with chronic lymphocytic leukaemia (CLL) and thrombocytopenia.29963527Jain P, Konoplev S, Benjamini O, Romagura J, Burger JABlood researchLong-term control of refractory follicular lymphoma after treatment of secondary acute promyelocytic leukemia with arsenic trioxide (As2O3) and all-trans retinoic acid (ATRA). Blood Res. 2018 Jun; 53(2):169-172.Blood Res2018-06-25T00:00:002018Long-term control of refractory follicular lymphoma after treatment of secondary acute promyelocytic leukemia with arsenic trioxide (As2O3) and all-trans retinoic acid (ATRA).30115541Kadia TM, Cortes J, Ravandi F, Jabbour E, Konopleva M, Benton CB, Burger J, Sasaki K, Borthakur G, DiNardo CD, Pemmaraju N, Daver N, Ferrajoli A, Wang X, Patel K, Jorgensen JL, Wang S, O'Brien S, Pierce S, Tuttle C, Estrov Z, Verstovsek S, Garcia-Manero G, Kantarjian HThe Lancet. HaematologyCladribine and low-dose cytarabine alternating with decitabine as front-line therapy for elderly patients with acute myeloid leukaemia: a phase 2 single-arm trial. Lancet Haematol. 2018 Sep; 5(9):e411-e421.Lancet Haematol2018-08-13T00:00:002018Cladribine and low-dose cytarabine alternating with decitabine as front-line therapy for elderly patients with acute myeloid leukaemia: a phase 2 single-arm trial.30307606Assi R, Garcia-Manero G, Ravandi F, Borthakur G, Daver NG, Jabbour E, Burger J, Estrov Z, Dinardo CD, Alvarado Y, Hendrickson S, Ferrajoli A, Wierda W, Cortes J, Kantarjian H, Kadia TMCancerAddition of eltrombopag to immunosuppressive therapy in patients with newly diagnosed aplastic anemia. Cancer. 2018 11 01; 124(21):4192-4201.Cancer2018-10-11T00:00:002018Addition of eltrombopag to immunosuppressive therapy in patients with newly diagnosed aplastic anemia.30307611Jabbour E, Sasaki K, Ravandi F, Huang X, Short NJ, Khouri M, Kebriaei P, Burger J, Khoury J, Jorgensen J, Jain N, Konopleva M, Garcia-Manero G, Kadia T, Cortes J, Jacob J, Montalbano K, Garris R, O'Brien S, Kantarjian HMCancerChemoimmunotherapy with inotuzumab ozogamicin combined with mini-hyper-CVD, with or without blinatumomab, is highly effective in patients with Philadelphia chromosome-negative acute lymphoblastic leukemia in first salvage. Cancer. 2018 10 15; 124(20):4044-4055.Cancer2018-10-11T00:00:002018Chemoimmunotherapy with inotuzumab ozogamicin combined with mini-hyper-CVD, with or without blinatumomab, is highly effective in patients with Philadelphia chromosome-negative acute lymphoblastic leukemia in first salvage.30319961Boddu P, Borthakur G, Koneru M, Huang X, Naqvi K, Wierda W, Bose P, Jabbour E, Estrov Z, Burger J, Alvarado Y, Deshmukh A, Patel A, Cavazos A, Han L, Cortes JE, Kantarjian H, Andreeff M, Konopleva MFrontiers in oncologyInitial Report of a Phase I Study of LY2510924, Idarubicin, and Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia. Front Oncol. 2018; 8:369.Front Oncol2018-09-24T00:00:002018Initial Report of a Phase I Study of LY2510924, Idarubicin, and Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia.29765537Rozovski U, Harris DM, Li P, Liu Z, Jain P, Ferrajoli A, Burger J, Thompson P, Jain N, Wierda W, Keating MJ, Estrov ZOncotargetSTAT3-activated CD36 facilitates fatty acid uptake in chronic lymphocytic leukemia cells. Oncotarget. 2018 Apr 20; 9(30):21268-21280.Oncotarget2018-04-20T00:00:002018STAT3-activated CD36 facilitates fatty acid uptake in chronic lymphocytic leukemia cells.29769624Thompson PA, Peterson CB, Strati P, Jorgensen J, Keating MJ, O'Brien SM, Ferrajoli A, Burger JA, Estrov Z, Jain N, Kadia TM, Borthakur G, DiNardo CD, Daver N, Jabbour E, Wierda WGLeukemiaSerial minimal residual disease (MRD) monitoring during first-line FCR treatment for CLL may direct individualized therapeutic strategies. Leukemia. 2018 11; 32(11):2388-2398.Leukemia2018-04-17T00:00:002018Serial minimal residual disease (MRD) monitoring during first-line FCR treatment for CLL may direct individualized therapeutic strategies.29777163Burger JA, O'Brien SNature reviews. Clinical oncologyEvolution of CLL treatment - from chemoimmunotherapy to targeted and individualized therapy. Nat Rev Clin Oncol. 2018 08; 15(8):510-527.Nat Rev Clin Oncol2018-08-01T00:00:002018Evolution of CLL treatment - from chemoimmunotherapy to targeted and individualized therapy.29880603Barr PM, Robak T, Owen C, Tedeschi A, Bairey O, Bartlett NL, Burger JA, Hillmen P, Coutre S, Devereux S, Grosicki S, McCarthy H, Li J, Simpson D, Offner F, Moreno C, Zhou C, Styles L, James D, Kipps TJ, Ghia PHaematologicaSustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2. Haematologica. 2018 09; 103(9):1502-1510.Haematologica2018-06-07T00:00:002018Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2.30028037Ohanian M, Garcia-Manero G, Levis M, Jabbour E, Daver N, Borthakur G, Kadia T, Pierce S, Burger J, Richie MA, Patel K, Andreeff M, Estrov Z, Cortes J, Kantarjian H, Ravandi FAmerican journal of hematologySorafenib Combined with 5-azacytidine in Older Patients with Untreated FLT3-ITD Mutated Acute Myeloid Leukemia. Am J Hematol. 2018 09; 93(9):1136-1141.Am J Hematol2018-08-31T00:00:002018Sorafenib Combined with 5-azacytidine in Older Patients with Untreated FLT3-ITD Mutated Acute Myeloid Leukemia.30094870O'Brien S, Patel M, Kahl BS, Horwitz SM, Foss FM, Porcu P, Jones J, Burger J, Jain N, Allen K, Faia K, Douglas M, Stern HM, Sweeney J, Kelly P, Kelly V, Flinn IAmerican journal of hematologyDuvelisib, an oral dual PI3K-d,? inhibitor, shows clinical and pharmacodynamic activity in chronic lymphocytic leukemia and small lymphocytic lymphoma in a phase 1 study. Am J Hematol. 2018 11; 93(11):1318-1326.Am J Hematol2018-10-20T00:00:002018Duvelisib, an oral dual PI3K-d,? inhibitor, shows clinical and pharmacodynamic activity in chronic lymphocytic leukemia and small lymphocytic lymphoma in a phase 1 study.30592080Hamlin PA, Flinn IW, Wagner-Johnston N, Burger JA, Coffey GP, Conley PB, Michelson G, Leeds JM, Der K, Kim Y, Sabalvaro-Torres A, Birrell M, Pandey A, Curnutte JT, Patel MRAmerican journal of hematologyEfficacy and safety of the dual SYK/JAK inhibitor cerdulatinib in patients with relapsed or refractory B-cell malignancies: Results of a phase I study. Am J Hematol. 2019 04; 94(4):E90-E93.Am J Hematol2019-01-08T00:00:002019Efficacy and safety of the dual SYK/JAK inhibitor cerdulatinib in patients with relapsed or refractory B-cell malignancies: Results of a phase I study.30739324Burger JA, Cramer P, Barr PM, Dilhuydy MS, Mato A, Byrd JC, Chang S, Graef T, Lin T, Tedeschi ABritish journal of haematologyIbrutinib provides favourable survival outcomes in patients with comorbidities versus established therapies. Br J Haematol. 2019 07; 186(1):175-180.Br J Haematol2019-02-10T00:00:002019Ibrutinib provides favourable survival outcomes in patients with comorbidities versus established therapies.30740654Wierda WG, Byrd JC, O'Brien S, Coutre S, Barr PM, Furman RR, Kipps TJ, Burger JA, Stevens DA, Sharman J, Ghia P, Flinn IW, Zhou C, Ninomoto J, James DF, Tam CSBritish journal of haematologyTumour debulking and reduction in predicted risk of tumour lysis syndrome with single-agent ibrutinib in patients with chronic lymphocytic leukaemia. Br J Haematol. 2019 07; 186(1):184-188.Br J Haematol2019-02-10T00:00:002019Tumour debulking and reduction in predicted risk of tumour lysis syndrome with single-agent ibrutinib in patients with chronic lymphocytic leukaemia.30506764Brown JR, Moslehi J, Ewer MS, O'Brien SM, Ghia P, Cymbalista F, Shanafelt TD, Fraser G, Rule S, Coutre SE, Dilhuydy MS, Cramer P, Jaeger U, Dreyling M, Byrd JC, Treon S, Liu EY, Chang S, Bista A, Vempati R, Boornazian L, Valentino R, Reddy V, Mahler M, Yang H, Graef T, Burger JABritish journal of haematologyIncidence of and risk factors for major haemorrhage in patients treated with ibrutinib: An integrated analysis. Br J Haematol. 2019 02; 184(4):558-569.Br J Haematol2018-12-02T00:00:002018Incidence of and risk factors for major haemorrhage in patients treated with ibrutinib: An integrated analysis.30508305Kanagal-Shamanna R, Jain P, Patel KP, Routbort M, Bueso-Ramos C, Alhalouli T, Khoury JD, Luthra R, Ferrajoli A, Keating M, Jain N, Burger J, Estrov Z, Wierda W, Kantarjian HM, Medeiros LJCancerTargeted multigene deep sequencing of Bruton tyrosine kinase inhibitor-resistant chronic lymphocytic leukemia with disease progression and Richter transformation. Cancer. 2019 02 15; 125(4):559-574.Cancer2018-12-03T00:00:002018Targeted multigene deep sequencing of Bruton tyrosine kinase inhibitor-resistant chronic lymphocytic leukemia with disease progression and Richter transformation.30709431Nastoupil LJ, Lunning MA, Vose JM, Schreeder MT, Siddiqi T, Flowers CR, Cohen JB, Burger JA, Wierda WG, O'Brien S, Sportelli P, Miskin HP, Purdom MA, Weiss MS, Fowler NHThe Lancet. HaematologyTolerability and activity of ublituximab, umbralisib, and ibrutinib in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: a phase 1 dose escalation and expansion trial. Lancet Haematol. 2019 Feb; 6(2):e100-e109.Lancet Haematol2019-02-01T00:00:002019Tolerability and activity of ublituximab, umbralisib, and ibrutinib in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: a phase 1 dose escalation and expansion trial.30632839Boddu P, Gibbons J, Burger J, Sivina M, Thakral B, Kanagal-Shamanna R, Ferrajoli ALeukemia & lymphomaCo-occurrence of chronic myeloid leukemia with chronic lymphocytic leukemia: a report of two cases. Leuk Lymphoma. 2019 06; 60(6):1568-1571.Leuk Lymphoma2019-01-11T00:00:002019Co-occurrence of chronic myeloid leukemia with chronic lymphocytic leukemia: a report of two cases.30530801Burger JA, Sivina M, Jain N, Kim E, Kadia T, Estrov Z, Nogueras-Gonzalez GM, Huang X, Jorgensen J, Li J, Cheng M, Clow F, Ohanian M, Andreeff M, Mathew T, Thompson P, Kantarjian H, O'Brien S, Wierda WG, Ferrajoli A, Keating MJBloodRandomized trial of ibrutinib vs ibrutinib plus rituximab in patients with chronic lymphocytic leukemia. Blood. 2019 03 07; 133(10):1011-1019.Blood2018-12-07T00:00:002018Randomized trial of ibrutinib vs ibrutinib plus rituximab in patients with chronic lymphocytic leukemia.30767298O'Brien SM, Byrd JC, Hillmen P, Coutre S, Brown JR, Barr PM, Barrientos JC, Devereux S, Robak T, Reddy NM, Kipps TJ, Tedeschi A, Cymbalista F, Ghia P, Chang S, Ninomoto J, James DF, Burger JAAmerican journal of hematologyOutcomes with ibrutinib by line of therapy and post-ibrutinib discontinuation in patients with chronic lymphocytic leukemia: Phase 3 analysis. Am J Hematol. 2019 05; 94(5):554-562.Am J Hematol2019-03-08T00:00:002019Outcomes with ibrutinib by line of therapy and post-ibrutinib discontinuation in patients with chronic lymphocytic leukemia: Phase 3 analysis.D015451Disorders29023900.403239Leukemia, Lymphocytic, Chronic, B-CellAuthorship 94105617Authorship 9424734Authorship 942515130842083Byrd JC, Hillmen P, O'Brien S, Barrientos JC, Reddy NM, Coutre S, Tam CS, Mulligan SP, Jaeger U, Barr PM, Furman RR, Kipps TJ, Thornton P, Moreno C, Montillo M, Pagel JM, Burger JA, Woyach JA, Dai S, Vezan R, James DF, Brown JRBloodLong-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab. Blood. 2019 05 09; 133(19):2031-2042.Blood2019-03-06T00:00:002019Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab.30728153Burger JAClinical cancer research : an official journal of the American Association for Cancer ResearchGoing through Changes: Surface IgM Levels during CLL Therapy with Ibrutinib. Clin Cancer Res. 2019 04 15; 25(8):2372-2374.Clin Cancer Res2019-02-06T00:00:002019Going through Changes: Surface IgM Levels during CLL Therapy with Ibrutinib.30814061Morande PE, Sivina M, Uriepero A, Seija N, Berca C, Fresia P, Landoni AI, Di Noia JM, Burger JA, Oppezzo PBloodIbrutinib therapy downregulates AID enzyme and proliferative fractions in chronic lymphocytic leukemia. Blood. 2019 05 09; 133(19):2056-2068.Blood2019-02-27T00:00:002019Ibrutinib therapy downregulates AID enzyme and proliferative fractions in chronic lymphocytic leukemia.Authorship 943718330555163Ten Hacken E, Gounari M, Ghia P, Burger JALeukemiaThe importance of B cell receptor isotypes and stereotypes in chronic lymphocytic leukemia. Leukemia. 2019 02; 33(2):287-298.Leukemia2018-12-16T00:00:002018The importance of B cell receptor isotypes and stereotypes in chronic lymphocytic leukemia.Authorship 945682431005650Vitale C, Falchi L, Ciccone M, Burger J, Pemmaraju N, Borthakur G, Wierda WG, Keating MJ, Ferrajoli AJournal of geriatric oncologyOfatumumab is safe and effective as front-line treatment in older patients with chronic lymphocytic leukemia and severe co-morbidities, including other malignancies. J Geriatr Oncol. 2020 01; 11(1):19-23.J Geriatr Oncol2019-04-18T00:00:002019Ofatumumab is safe and effective as front-line treatment in older patients with chronic lymphocytic leukemia and severe co-morbidities, including other malignancies.Authorship 946808831076409Strati P, Takahashi K, Peterson CB, Keating MJ, Thompson PA, Daver NG, Jain N, Burger JA, Estrov Z, O'Brien SM, Kantarjian HM, Wierda WG, Futreal PA, Ferrajoli ABlood advancesEfficacy and predictors of response of lenalidomide and rituximab in patients with treatment-naive and relapsed CLL. Blood Adv. 2019 05 14; 3(9):1533-1539.Blood Adv2019-05-14T00:00:002019Efficacy and predictors of response of lenalidomide and rituximab in patients with treatment-naive and relapsed CLL.19228923Kurtova AV, Tamayo AT, Ford RJ, Burger JABloodMantle cell lymphoma cells express high levels of CXCR4, CXCR5, and VLA-4 (CD49d): importance for interactions with the stromal microenvironment and specific targeting. Blood. 2009 May 07; 113(19):4604-13.Blood2009-02-19T00:00:002009Mantle cell lymphoma cells express high levels of CXCR4, CXCR5, and VLA-4 (CD49d): importance for interactions with the stromal microenvironment and specific targeting.19318683Niedermeier M, Hennessy BT, Knight ZA, Henneberg M, Hu J, Kurtova AV, Wierda WG, Keating MJ, Shokat KM, Burger JABloodIsoform-selective phosphoinositide 3'-kinase inhibitors inhibit CXCR4 signaling and overcome stromal cell-mediated drug resistance in chronic lymphocytic leukemia: a novel therapeutic approach. Blood. 2009 May 28; 113(22):5549-57.Blood2009-03-24T00:00:002009Isoform-selective phosphoinositide 3'-kinase inhibitors inhibit CXCR4 signaling and overcome stromal cell-mediated drug resistance in chronic lymphocytic leukemia: a novel therapeutic approach.19491390Quiroga MP, Balakrishnan K, Kurtova AV, Sivina M, Keating MJ, Wierda WG, Gandhi V, Burger JABloodB-cell antigen receptor signaling enhances chronic lymphocytic leukemia cell migration and survival: specific targeting with a novel spleen tyrosine kinase inhibitor, R406. Blood. 2009 Jul 30; 114(5):1029-37.Blood2009-06-02T00:00:002009B-cell antigen receptor signaling enhances chronic lymphocytic leukemia cell migration and survival: specific targeting with a novel spleen tyrosine kinase inhibitor, R406.19762485Kurtova AV, Balakrishnan K, Chen R, Ding W, Schnabl S, Quiroga MP, Sivina M, Wierda WG, Estrov Z, Keating MJ, Shehata M, J?ger U, Gandhi V, Kay NE, Plunkett W, Burger JABloodDiverse marrow stromal cells protect CLL cells from spontaneous and drug-induced apoptosis: development of a reliable and reproducible system to assess stromal cell adhesion-mediated drug resistance. Blood. 2009 Nov 12; 114(20):4441-50.Blood2009-09-17T00:00:002009Diverse marrow stromal cells protect CLL cells from spontaneous and drug-induced apoptosis: development of a reliable and reproducible system to assess stromal cell adhesion-mediated drug resistance.23782158Byrd JC, Furman RR, Coutre SE, Flinn IW, Burger JA, Blum KA, Grant B, Sharman JP, Coleman M, Wierda WG, Jones JA, Zhao W, Heerema NA, Johnson AJ, Sukbuntherng J, Chang BY, Clow F, Hedrick E, Buggy JJ, James DF, O'Brien SThe New England journal of medicineTargeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013 Jul 04; 369(1):32-42.N Engl J Med2013-06-19T00:00:002013Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia.Authorship 9490951231196847Coutre SE, Byrd JC, Hillmen P, Barrientos JC, Barr PM, Devereux S, Robak T, Kipps TJ, Schuh A, Moreno C, Furman RR, Burger JA, O'Dwyer M, Ghia P, Valentino R, Chang S, Dean JP, James DF, O'Brien SMBlood advancesLong-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies. Blood Adv. 2019 06 25; 3(12):1799-1807.Blood Adv2019-06-25T00:00:002019Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies.Authorship 9519812Authorship 9521491131305193Alfayez M, Burger JA, Kadia T, Xu TH, Szvalb AD, Pemmaraju NLeukemia & lymphomaPlesiomonas shigelloides gastroenteritis in a patient with chronic lymphocytic leukemia. Leuk Lymphoma. 2019 12; 60(13):3341-3342.Leuk Lymphoma2019-07-15T00:00:002019Plesiomonas shigelloides gastroenteritis in a patient with chronic lymphocytic leukemia.31315913Yigit B, Wang N, Ten Hacken E, Chen SS, Bhan AK, Suarez-Fueyo A, Katsuyama E, Tsokos GC, Chiorazzi N, Wu CJ, Burger JA, Herzog RW, Engel P, Terhorst CCancer immunology researchSLAMF6 as a Regulator of Exhausted CD8+ T Cells in Cancer. Cancer Immunol Res. 2019 09; 7(9):1485-1496.Cancer Immunol Res2019-07-17T00:00:002019SLAMF6 as a Regulator of Exhausted CD8+ T Cells in Cancer.Authorship 9525434Authorship 952608531340982Tam CS, Trotman J, Opat S, Burger JA, Cull G, Gottlieb D, Harrup R, Johnston PB, Marlton P, Munoz J, Seymour JF, Simpson D, Tedeschi A, Elstrom R, Yu Y, Tang Z, Han L, Huang J, Novotny W, Wang L, Roberts AWBloodPhase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL. Blood. 2019 09 12; 134(11):851-859.Blood2019-07-24T00:00:002019Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL.31344256Strati P, Wang F, Tambaro FP, Thompson PA, Burger JA, Jain N, Ferrajoli A, Bose P, Estrov Z, Keating MJ, Futreal A, Takahashi K, Wierda WGBritish journal of haematologyThe landscape of genetic mutations in patients with chronic lymphocytic leukaemia and complex karyotype. Br J Haematol. 2019 10; 187(1):e1-e4.Br J Haematol2019-07-25T00:00:002019The landscape of genetic mutations in patients with chronic lymphocytic leukaemia and complex karyotype.Authorship 952833731352850Andritsos LA, Byrd JC, Cheverton P, Wu J, Sivina M, Kipps TJ, Burger JALeukemia & lymphomaA multicenter phase 1 study of plerixafor and rituximab in patients with chronic lymphocytic leukemia. Leuk Lymphoma. 2019 12; 60(14):3461-3469.Leuk Lymphoma2019-07-27T00:00:002019A multicenter phase 1 study of plerixafor and rituximab in patients with chronic lymphocytic leukemia.Authorship 9538541531413095Tedeschi A, Greil R, Demirkan F, Robak T, Moreno C, Barr PM, Anz B, Simpson D, Gaidano G, Bairey O, Stevens D, Gill D, Flinn IW, Kipps TJ, Burger JA, Lin J, Webb T, Fedorov V, Styles L, Gribben JGHaematologicaA cross-trial comparison of single-agent ibrutinib versus chlorambucil-obinutuzumab in previously untreated patients with chronic lymphocytic leukemia or small lymphocytic lymphoma. Haematologica. 2020 04; 105(4):e164-e168.Haematologica2019-08-14T00:00:002019A cross-trial comparison of single-agent ibrutinib versus chlorambucil-obinutuzumab in previously untreated patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.Authorship 9552593Authorship 9554001431502383Abou Dalle I, Kantarjian H, Burger J, Estrov Z, Ohanian M, Verstovsek S, Ravandi F, Borthakur G, Garcia-Manero G, Jabbour E, Cortes JCancer medicineEfficacy and safety of generic imatinib after switching from original imatinib in patients treated for chronic myeloid leukemia in the United States. Cancer Med. 2019 11; 8(15):6559-6565.Cancer Med2019-09-10T00:00:002019Efficacy and safety of generic imatinib after switching from original imatinib in patients treated for chronic myeloid leukemia in the United States.31512258Munir T, Brown JR, O'Brien S, Barrientos JC, Barr PM, Reddy NM, Coutre S, Tam CS, Mulligan SP, Jaeger U, Kipps TJ, Moreno C, Montillo M, Burger JA, Byrd JC, Hillmen P, Dai S, Szoke A, Dean JP, Woyach JAAmerican journal of hematologyFinal analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma. Am J Hematol. 2019 12; 94(12):1353-1363.Am J Hematol2019-10-13T00:00:002019Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma.Authorship 9557811031537528Thompson PA, Srivastava J, Peterson C, Strati P, Jorgensen JL, Hether T, Keating MJ, O'Brien SM, Ferrajoli A, Burger JA, Estrov Z, Jain N, Wierda WGBloodMinimal residual disease undetectable by next-generation sequencing predicts improved outcome in CLL after chemoimmunotherapy. Blood. 2019 11 28; 134(22):1951-1959.Blood2019-11-28T00:00:002019Minimal residual disease undetectable by next-generation sequencing predicts improved outcome in CLL after chemoimmunotherapy.Authorship 95599813Authorship 956090531553487Naqvi K, Jabbour E, Skinner J, Anderson K, Dellasala S, Yilmaz M, Ferrajoli A, Bose P, Thompson P, Alvarado Y, Jain N, Takahashi K, Burger J, Estrov Z, Borthakur G, Pemmaraju N, Paul S, Cortes J, Kantarjian HMCancerLong-term follow-up of lower dose dasatinib (50?mg daily) as frontline therapy in newly diagnosed chronic-phase chronic myeloid leukemia. Cancer. 2020 01 01; 126(1):67-75.Cancer2019-09-25T00:00:002019Long-term follow-up of lower dose dasatinib (50?mg daily) as frontline therapy in newly diagnosed chronic-phase chronic myeloid leukemia.31558467Lunning M, Vose J, Nastoupil L, Fowler N, Burger JA, Wierda WG, Schreeder MT, Siddiqi T, Flowers CR, Cohen JB, Sportelli P, Miskin HP, Weiss MS, O'Brien SBloodUblituximab and umbralisib in relapsed/refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood. 2019 11 21; 134(21):1811-1820.Blood2019-11-21T00:00:002019Ublituximab and umbralisib in relapsed/refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia.Authorship 957462131628428Burger JA, Barr PM, Robak T, Owen C, Ghia P, Tedeschi A, Bairey O, Hillmen P, Coutre SE, Devereux S, Grosicki S, McCarthy H, Simpson D, Offner F, Moreno C, Dai S, Lal I, Dean JP, Kipps TJLeukemiaLong-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study. Leukemia. 2020 03; 34(3):787-798.Leukemia2019-10-18T00:00:002019Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study.Authorship 957766731645416Rozovski U, Harris DM, Li P, Liu Z, Jain P, Ferrajoli A, Burger JA, Bose P, Thompson PA, Jain N, Wierda WG, Uziel O, Keating MJ, Estrov ZJournal of immunology (Baltimore, Md. : 1950)STAT3-Induced Wnt5a Provides Chronic Lymphocytic Leukemia Cells with Survival Advantage. J Immunol. 2019 12 01; 203(11):3078-3085.J Immunol2019-10-23T00:00:002019STAT3-Induced Wnt5a Provides Chronic Lymphocytic Leukemia Cells with Survival Advantage.Authorship 961569131764119Burger JACancer journal (Sudbury, Mass.)Bruton Tyrosine Kinase Inhibitors: Present and Future. Cancer J. 2019 Nov/Dec; 25(6):386-393.Cancer J2019-11-01T00:00:002019Bruton Tyrosine Kinase Inhibitors: Present and Future.Authorship 9629481231862959Kim E, Ten Hacken E, Sivina M, Clarke A, Thompson PA, Jain N, Ferrajoli A, Estrov Z, Keating MJ, Wierda WG, Bhalla KN, Burger JALeukemiaThe BET inhibitor GS-5829 targets chronic lymphocytic leukemia cells and their supportive microenvironment. Leukemia. 2020 06; 34(6):1588-1598.Leukemia2019-12-20T00:00:002019The BET inhibitor GS-5829 targets chronic lymphocytic leukemia cells and their supportive microenvironment.Authorship 9750971531895947Strati P, Schlette EJ, Solis Soto LM, Duenas DE, Sivina M, Kim E, Keating MJ, Wierda WG, Ferrajoli A, Kantarjian H, Estrov Z, Jain N, Thompson PA, Wistuba II, Burger JABloodAchieving complete remission in CLL patients treated with ibrutinib: clinical significance and predictive factors. Blood. 2020 02 13; 135(7):510-513.Blood2020-02-13T00:00:002020Achieving complete remission in CLL patients treated with ibrutinib: clinical significance and predictive factors.Authorship 979187932170867Sasaki K, Kantarjian H, Wierda W, Ravandi-Kashani F, Jorgensen J, Wang SA, Khoury J, Daver N, Burger J, Di Nardo CD, Jain N, Short NJ, Estrov Md Z, Konopleva Md PhD M, Ohanian DO M, Garcia-Manero G, Kadia T, Alvarado-Valero Y, Yilmaz M, Pierce S, Garris R, Ingram A, Cortes J, O'Brien S, Jabbour EAmerican journal of hematologyPhase 2 study of hyper-CMAD with liposomal vincristine for patients with newly diagnosed acute lymphoblastic leukemia. Am J Hematol. 2020 07; 95(7):734-739.Am J Hematol2020-04-24T00:00:002020Phase 2 study of hyper-CMAD with liposomal vincristine for patients with newly diagnosed acute lymphoblastic leukemia.Authorship 980282532209572Byrd JC, Furman RR, Coutre SE, Flinn IW, Burger JA, Blum K, Sharman JP, Wierda W, Zhao W, Heerema NA, Luan Y, Liu EA, Dean JP, O'Brien SClinical cancer research : an official journal of the American Association for Cancer ResearchIbrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 Study. Clin Cancer Res. 2020 08 01; 26(15):3918-3927.Clin Cancer Res2020-03-24T00:00:002020Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 Study.Authorship 989400232404571Kojima K, Burger JAJournal of clinical and experimental hematopathology : JCEHTreatment algorithm for Japanese patients with chronic lymphocytic leukemia in the era of novel targeted therapies. J Clin Exp Hematop. 2020 Dec 15; 60(4):130-137.J Clin Exp Hematop2020-05-13T00:00:002020Treatment algorithm for Japanese patients with chronic lymphocytic leukemia in the era of novel targeted therapies.Authorship 993128232611256de Castro CG, Gregianin LJ, Burger JALeukemia & lymphomaContinuous high-dose ivermectin appears to be safe in patients with acute myelogenous leukemia and could inform clinical repurposing for COVID-19 infection. Leuk Lymphoma. 2020 10; 61(10):2536-2537.Leuk Lymphoma2020-07-01T00:00:002020Continuous high-dose ivermectin appears to be safe in patients with acute myelogenous leukemia and could inform clinical repurposing for COVID-19 infection.Authorship 99446612Authorship 9946411132670522Malek AE, Gutierrez C, Mulanovich VE, Botdorf J, Chemaly RF, Shah S, McCall BM, Melancon JT, McConn KK, Borjan J, Raad II, Burger JA, Garcia-Manero G, Adachi JAMediterranean journal of hematology and infectious diseasesSuccessful Outcomes of Severe COVID-19 in Patient with Chronic Lymphocytic Leukemia: Diagnostic Challenges in Immunocompromised Hosts. Mediterr J Hematol Infect Dis. 2020; 12(1):e2020044.Mediterr J Hematol Infect Dis2020-07-01T00:00:002020Successful Outcomes of Severe COVID-19 in Patient with Chronic Lymphocytic Leukemia: Diagnostic Challenges in Immunocompromised Hosts.32681739Abaza Y, Kantarjian H, Alwash Y, Borthakur G, Champlin R, Kadia T, Garcia-Manero G, Daver N, Ravandi F, Verstovsek S, Burger J, Estrov Z, Ohanian M, Lim M, Pemmaraju N, Jabbour E, Cortes JAmerican journal of hematologyPhase I/II study of dasatinib in combination with decitabine in patients with accelerated or blast phase chronic myeloid leukemia. Am J Hematol. 2020 11; 95(11):1288-1295.Am J Hematol2020-08-12T00:00:002020Phase I/II study of dasatinib in combination with decitabine in patients with accelerated or blast phase chronic myeloid leukemia.Authorship 995637132726532Burger JAThe New England journal of medicineTreatment of Chronic Lymphocytic Leukemia. N Engl J Med. 2020 07 30; 383(5):460-473.N Engl J Med2020-07-30T00:00:002020Treatment of Chronic Lymphocytic Leukemia.Authorship 997880232833105Liu W, Burger JA, Xu J, Tang Z, Toruner G, Khanlari M, Medeiros LJ, Tang GAnnals of hematologyLPL deletion is associated with poorer response to ibrutinib-based treatments and overall survival in TP53-deleted chronic lymphocytic leukemia. Ann Hematol. 2020 Oct; 99(10):2343-2349.Ann Hematol2020-08-24T00:00:002020LPL deletion is associated with poorer response to ibrutinib-based treatments and overall survival in TP53-deleted chronic lymphocytic leukemia.Authorship 99914018Authorship 999291532896301DiNardo CD, Maiti A, Rausch CR, Pemmaraju N, Naqvi K, Daver NG, Kadia TM, Borthakur G, Ohanian M, Alvarado Y, Issa GC, Montalban-Bravo G, Short NJ, Yilmaz M, Bose P, Jabbour EJ, Takahashi K, Burger JA, Garcia-Manero G, Jain N, Kornblau SM, Thompson PA, Estrov Z, Masarova L, Sasaki K, Verstovsek S, Ferrajoli A, Weirda WG, Wang SA, Konoplev S, Chen Z, Pierce SA, Ning J, Qiao W, Ravandi F, Andreeff M, Welch JS, Kantarjian HM, Konopleva MYThe Lancet. Haematology10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial. Lancet Haematol. 2020 Oct; 7(10):e724-e736.Lancet Haematol2020-09-05T00:00:00202010-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial.32911375Solman IG, Blum LK, Hoh HY, Kipps TJ, Burger JA, Barrientos JC, O'Brien S, Mulligan SP, Kay NE, Hillmen P, Byrd JC, Lal ID, Dean JP, Mongan ALeukemia researchIbrutinib restores immune cell numbers and function in first-line and relapsed/refractory chronic lymphocytic leukemia. Leuk Res. 2020 10; 97:106432.Leuk Res2020-08-11T00:00:002020Ibrutinib restores immune cell numbers and function in first-line and relapsed/refractory chronic lymphocytic leukemia.Authorship 10033121333087831Sivina M, Xiao L, Kim E, Vaca A, Chen SS, Keating MJ, Ferrajoli A, Estrov Z, Jain N, Wierda WG, Huang X, Chiorazzi N, Burger JALeukemiaCXCL13 plasma levels function as a biomarker for disease activity in patients with chronic lymphocytic leukemia. Leukemia. 2021 06; 35(6):1610-1620.Leukemia2020-10-21T00:00:002020CXCL13 plasma levels function as a biomarker for disease activity in patients with chronic lymphocytic leukemia.Authorship 1012072333611131Solman IG, Blum LK, Burger JA, Kipps TJ, Dean JP, James DF, Mongan ALeukemia researchImpact of long-term ibrutinib treatment on circulating immune cells in previously untreated chronic lymphocytic leukemia. Leuk Res. 2021 03; 102:106520.Leuk Res2021-02-05T00:00:002021Impact of long-term ibrutinib treatment on circulating immune cells in previously untreated chronic lymphocytic leukemia.Authorship 10135262133689703Lazarian G, Yin S, Ten Hacken E, Sewastianik T, Uduman M, Font-Tello A, Gohil SH, Li S, Kim E, Joyal H, Billington L, Witten E, Zheng M, Huang T, Severgnini M, Lefebvre V, Rassenti LZ, Gutierrez C, Georgopoulos K, Ott CJ, Wang L, Kipps TJ, Burger JA, Livak KJ, Neuberg DS, Baran-Marszak F, Cymbalista F, Carrasco RD, Wu CJCancer cellA hotspot mutation in transcription factor IKZF3 drives B cell neoplasia via transcriptional dysregulation. Cancer Cell. 2021 03 08; 39(3):380-393.e8.Cancer Cell2021-03-08T00:00:002021A hotspot mutation in transcription factor IKZF3 drives B cell neoplasia via transcriptional dysregulation.Authorship 10137509Authorship 10141101733714981Chen R, Tsai J, Thompson PA, Chen Y, Xiong P, Liu C, Burrows F, Sivina M, Burger JA, Keating MJ, Wierda WG, Plunkett WBlood cancer journalThe multi-kinase inhibitor TG02 induces apoptosis and blocks B-cell receptor signaling in chronic lymphocytic leukemia through dual mechanisms of action. Blood Cancer J. 2021 03 13; 11(3):57.Blood Cancer J2021-03-13T00:00:002021The multi-kinase inhibitor TG02 induces apoptosis and blocks B-cell receptor signaling in chronic lymphocytic leukemia through dual mechanisms of action.33740268Jabbour E, Sasaki K, Short NJ, Ravandi F, Huang X, Khoury JD, Kanagal-Shamanna R, Jorgensen J, Khouri IF, Kebriaei P, Jain N, Alvarado Y, Kadia TM, Paul S, Garcia-Manero G, Dabaja BS, Burger JA, DiNardo CD, Daver NA, Montalban-Bravo G, Yilmaz M, Ohanian M, Ferrajoli A, Jacob J, Rostykus M, Garris R, O'Brien S, Kantarjian HMCancerLong-term follow-up of salvage therapy using a combination of inotuzumab ozogamicin and mini-hyper-CVD with or without blinatumomab in relapsed/refractory Philadelphia chromosome-negative acute lymphoblastic leukemia. Cancer. 2021 06 15; 127(12):2025-2038.Cancer2021-03-19T00:00:002021Long-term follow-up of salvage therapy using a combination of inotuzumab ozogamicin and mini-hyper-CVD with or without blinatumomab in relapsed/refractory Philadelphia chromosome-negative acute lymphoblastic leukemia.Authorship 10156352133792630Maiti A, DiNardo CD, Wang SA, Jorgensen J, Kadia TM, Daver NG, Short NJ, Yilmaz M, Pemmaraju N, Borthakur G, Bose P, Issa GC, Ferrajoli A, Jabbour EJ, Jain N, Garcia-Manero G, Ohanian M, Takahashi K, Montalban-Bravo G, Masarova L, Burger JA, Thompson PA, Verstovsek S, Sasaki K, Andreeff M, Rausch CR, Montalbano KS, Pierce S, Qiao W, Ning J, Kantarjian HM, Konopleva MY, Ravandi FBlood advancesPrognostic value of measurable residual disease after venetoclax and decitabine in acute myeloid leukemia. Blood Adv. 2021 04 13; 5(7):1876-1883.Blood Adv2021-04-13T00:00:002021Prognostic value of measurable residual disease after venetoclax and decitabine in acute myeloid leukemia.Authorship 10170861333901324Kadia TM, Ravandi F, Borthakur G, Konopleva M, DiNardo CD, Daver N, Pemmaraju N, Kanagal-Shamanna R, Wang X, Huang X, Pierce S, Rausch C, Burger J, Ferrajoli A, Jain N, Popat U, Estrov Z, Verstovsek S, Jabbour E, Garcia-Manero G, Kantarjian HAmerican journal of hematologyLong-term results of low-intensity chemotherapy with clofarabine or cladribine combined with low-dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemia. Am J Hematol. 2021 08 01; 96(8):914-924.Am J Hematol2021-05-26T00:00:002021Long-term results of low-intensity chemotherapy with clofarabine or cladribine combined with low-dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemia.Authorship 10175211333935280Ferrer G, Jung B, Chiu PY, Aslam R, Palacios F, Mazzarello AN, Vergani S, Bagnara D, Chen SS, Yancopoulos S, Xochelli A, Yan XJ, Burger JA, Barrientos JC, Kolitz JE, Allen SL, Stamatopoulos K, Rai KR, Sherry B, Chiorazzi NLeukemiaMyeloid-derived suppressor cell subtypes differentially influence T-cell function, T-helper subset differentiation, and clinical course in CLL. Leukemia. 2021 11; 35(11):3163-3175.Leukemia2021-05-02T00:00:002021Myeloid-derived suppressor cell subtypes differentially influence T-cell function, T-helper subset differentiation, and clinical course in CLL.Authorship 1018248733973230Cherng HJ, Jammal N, Paul S, Wang X, Sasaki K, Thompson P, Burger J, Ferrajoli A, Estrov Z, O'Brien S, Keating M, Wierda WG, Jain NBritish journal of haematologyClinical and molecular characteristics and treatment patterns of adolescent and young adult patients with chronic lymphocytic leukaemia. Br J Haematol. 2021 07; 194(1):61-68.Br J Haematol2021-05-10T00:00:002021Clinical and molecular characteristics and treatment patterns of adolescent and young adult patients with chronic lymphocytic leukaemia.Authorship 1018883334007049Jain N, Thompson P, Burger J, Ferrajoli A, Takahashi K, Estrov Z, Borthakur G, Bose P, Kadia T, Pemmaraju N, Sasaki K, Konopleva M, Jabbour E, Garg N, Wang X, Kanagal-Shamanna R, Patel K, Wang W, Jorgensen J, Wang S, Lopez W, Ayala A, Plunkett W, Gandhi V, Kantarjian H, O'Brien S, Keating M, Wierda WGLeukemiaIbrutinib, fludarabine, cyclophosphamide, and obinutuzumab (iFCG) regimen for chronic lymphocytic leukemia (CLL) with mutated IGHV and without TP53 aberrations. Leukemia. 2021 12; 35(12):3421-3429.Leukemia2021-05-18T00:00:002021Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (iFCG) regimen for chronic lymphocytic leukemia (CLL) with mutated IGHV and without TP53 aberrations.Authorship 1020770534110383Jain N, Keating M, Thompson P, Ferrajoli A, Burger JA, Borthakur G, Takahashi K, Estrov Z, Sasaki K, Fowler N, Kadia T, Konopleva M, Alvarado Y, Yilmaz M, DiNardo C, Bose P, Ohanian M, Pemmaraju N, Jabbour E, Kanagal-Shamanna R, Patel K, Wang W, Jorgensen J, Wang SA, Garg N, Wang X, Wei C, Cruz N, Ayala A, Plunkett W, Kantarjian H, Gandhi V, Wierda WGJAMA oncologyIbrutinib Plus Venetoclax for First-line Treatment of Chronic Lymphocytic Leukemia: A Nonrandomized Phase 2 Trial. JAMA Oncol. 2021 Aug 01; 7(8):1213-1219.JAMA Oncol2021-08-01T00:00:002021Ibrutinib Plus Venetoclax for First-line Treatment of Chronic Lymphocytic Leukemia: A Nonrandomized Phase 2 Trial.Authorship 1024013234177947Smith CIE, Burger JAFrontiers in immunologyResistance Mutations to BTK Inhibitors Originate From the NF-?B but Not From the PI3K-RAS-MAPK Arm of the B Cell Receptor Signaling Pathway. Front Immunol. 2021; 12:689472.Front Immunol2021-06-10T00:00:002021Resistance Mutations to BTK Inhibitors Originate From the NF-?B but Not From the PI3K-RAS-MAPK Arm of the B Cell Receptor Signaling Pathway.Authorship 10278721Authorship 1027998134410355Burger JABloodCLL cells are moved by the MARCKS brothers. Blood. 2021 08 19; 138(7):503-504.Blood2021-08-19T00:00:002021CLL cells are moved by the MARCKS brothers.34398554Burger JACancer journal (Sudbury, Mass.)Integrating New Therapies for Chronic Lymphocytic Leukemia. Cancer J. 2021 Jul-Aug 01; 27(4):275-285.Cancer J2021-07-01T00:00:002021Integrating New Therapies for Chronic Lymphocytic Leukemia.Authorship 1029726934521099Sivina M, Kim E, Wierda WG, Ferrajoli A, Jain N, Thompson P, Kantarjian H, Keating M, Burger JABloodIbrutinib induces durable remissions in treatment-na?ve patients with CLL and 17p deletion and/or TP53 mutations. Blood. 2021 12 16; 138(24):2589-2592.Blood2021-12-16T00:00:002021Ibrutinib induces durable remissions in treatment-na?ve patients with CLL and 17p deletion and/or TP53 mutations.Authorship 10312731034625713van Dijk AD, Griffen TL, Qiu YH, Hoff FW, Toro E, Ruiz K, Ruvolo PP, Lillard JW, de Bont ESJM, Burger JA, Wierda W, Kornblau SMLeukemiaRPPA-based proteomics recognizes distinct epigenetic signatures in chronic lymphocytic leukemia with clinical consequences. Leukemia. 2022 03; 36(3):712-722.Leukemia2021-10-08T00:00:002021RPPA-based proteomics recognizes distinct epigenetic signatures in chronic lymphocytic leukemia with clinical consequences.Authorship 1033244834813501Mazzarello AN, Gentner-G?bel E, D?hren-von Minden M, Tarasenko TN, Nicol? A, Ferrer G, Vergani S, Liu Y, Bagnara D, Rai KR, Burger JA, McGuire PJ, Maity PC, Jumaa H, Chiorazzi NThe Journal of clinical investigationB cell receptor isotypes differentially associate with cell signaling, kinetics, and outcome in chronic lymphocytic leukemia. J Clin Invest. 2022 01 18; 132(2).J Clin Invest2022-01-18T00:00:002022B cell receptor isotypes differentially associate with cell signaling, kinetics, and outcome in chronic lymphocytic leukemia.Authorship 1035639234915592Cull G, Burger JA, Opat S, Gottlieb D, Verner E, Trotman J, Marlton P, Munoz J, Johnston P, Simpson D, Stern JC, Prathikanti R, Wu K, Novotny W, Huang J, Tam CSBritish journal of haematologyZanubrutinib for treatment-na?ve and relapsed/refractory chronic lymphocytic leukaemia: long-term follow-up of the phase I/II AU-003 study. Br J Haematol. 2022 03; 196(5):1209-1218.Br J Haematol2021-12-16T00:00:002021Zanubrutinib for treatment-na?ve and relapsed/refractory chronic lymphocytic leukaemia: long-term follow-up of the phase I/II AU-003 study.Authorship 1037152135014928Burger JA, Robak T, Demirkan F, Bairey O, Moreno C, Simpson D, Munir T, Stevens DA, Dai S, Cheung LWK, Kwei K, Lal I, Hsu E, Kipps TJ, Tedeschi ALeukemia & lymphomaUp to 6.5 years (median 4 years) of follow-up of first-line ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma and high-risk genomic features: integrated analysis of two phase 3 studies. Leuk Lymphoma. 2022 06; 63(6):1375-1386.Leuk Lymphoma2022-01-11T00:00:002022Up to 6.5 years (median 4 years) of follow-up of first-line ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma and high-risk genomic features: integrated analysis of two phase 3 studies.Authorship 103978114Authorship 1041209735225133Mukherjee A, Milton DR, Jabbour EJ, Gulbis AM, Kadia T, Jain N, Ledesma C, Burger J, Ferrajoli A, Wierda W, Medeiros LJ, Kantarjian H, Champlin R, Khouri IFLeukemia & lymphomaClinical outcome of allogeneic stem cell transplantation in patients with B-cell lymphoid malignancies following treatment with targeted small molecule inhibitors. Leuk Lymphoma. 2022 04; 63(4):885-893.Leuk Lymphoma2022-02-27T00:00:002022Clinical outcome of allogeneic stem cell transplantation in patients with B-cell lymphoid malignancies following treatment with targeted small molecule inhibitors.35149845Vaca AM, Ioannou N, Sivina M, Vlachonikola E, Clise-Dwyer K, Kim E, Li D, Ma Q, Ferrajoli A, Estrov Z, Wierda WG, Patten PEM, Ramsay AG, Burger JALeukemiaActivation and expansion of T-follicular helper cells in chronic lymphocytic leukemia nurselike cell co-cultures. Leukemia. 2022 05; 36(5):1324-1335.Leukemia2022-02-11T00:00:002022Activation and expansion of T-follicular helper cells in chronic lymphocytic leukemia nurselike cell co-cultures.Authorship 10433394Authorship 10441812035377947Barr PM, Owen C, Robak T, Tedeschi A, Bairey O, Burger JA, Hillmen P, Coutre SE, Dearden C, Grosicki S, McCarthy H, Li JY, Offner F, Moreno C, Zhou C, Hsu E, Szoke A, Kipps TJ, Ghia PBlood advancesUp to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia. Blood Adv. 2022 06 14; 6(11):3440-3450.Blood Adv2022-06-14T00:00:002022Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia.35442137Short NJ, Borthakur G, Pemmaraju N, Dinardo CD, Kadia TM, Jabbour E, Konopleva M, Macaron W, Ning J, Ma J, Pierce S, Alvarado Y, Sasaki K, Takahashi K, Estrov Z, Masarova L, Issa GC, Montalban-Bravo G, Andreeff M, Burger JA, Miller D, Alexander L, Naing A, Garcia-Manero G, Ravandi F, Daver NLeukemia & lymphomaA multi-arm phase Ib/II study designed for rapid, parallel evaluation of novel immunotherapy combinations in relapsed/refractory acute myeloid leukemia. Leuk Lymphoma. 2022 09; 63(9):2161-2170.Leuk Lymphoma2022-04-20T00:00:002022A multi-arm phase Ib/II study designed for rapid, parallel evaluation of novel immunotherapy combinations in relapsed/refractory acute myeloid leukemia.24332241O'Brien S, Furman RR, Coutre SE, Sharman JP, Burger JA, Blum KA, Grant B, Richards DA, Coleman M, Wierda WG, Jones JA, Zhao W, Heerema NA, Johnson AJ, Izumi R, Hamdy A, Chang BY, Graef T, Clow F, Buggy JJ, James DF, Byrd JCThe Lancet. OncologyIbrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial. Lancet Oncol. 2014 Jan; 15(1):48-58.Lancet Oncol2013-12-10T00:00:002013Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial.Authorship 10459425Authorship 1046283935595309Rozovski U, Veletic I, Harris DM, Li P, Liu Z, Jain P, Manshouri T, Ferrajoli A, Burger JA, Bose P, Thompson PA, Jain N, Wierda WG, Verstovsek S, Keating MJ, Estrov ZJournal of immunology (Baltimore, Md. : 1950)STAT3 Activates the Pentraxin 3 Gene in Chronic Lymphocytic Leukemia Cells. J Immunol. 2022 06 15; 208(12):2847-2855.J Immunol2022-05-20T00:00:002022STAT3 Activates the Pentraxin 3 Gene in Chronic Lymphocytic Leukemia Cells.35567779Cherng HJ, Khwaja R, Kanagal-Shamanna R, Tang G, Burger J, Thompson P, Ferrajoli A, Estrov Z, Sasaki K, Sampath D, Wang X, Kantarjian H, Keating M, Wierda WG, Jain NAmerican journal of hematologyTP53-altered chronic lymphocytic leukemia treated with firstline Bruton's tyrosine kinase inhibitor-based therapy: A retrospective analysis. Am J Hematol. 2022 08; 97(8):1005-1012.Am J Hematol2022-05-30T00:00:002022TP53-altered chronic lymphocytic leukemia treated with firstline Bruton's tyrosine kinase inhibitor-based therapy: A retrospective analysis.Authorship 106136910Authorship 10548716Authorship 105530427Authorship 1058551636672456Woyach JA, Barr PM, Kipps TJ, Barrientos JC, Ahn IE, Ghia P, Girardi V, Hsu E, Jermain M, Burger JACancersCharacteristics and Clinical Outcomes of Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Receiving Ibrutinib for =5 Years in the RESONATE-2 Study. Cancers (Basel). 2023 Jan 13; 15(2).Cancers (Basel)2023-01-13T00:00:002023Characteristics and Clinical Outcomes of Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Receiving Ibrutinib for =5 Years in the RESONATE-2 Study.35927489Knisbacher BA, Lin Z, Hahn CK, Nadeu F, Duran-Ferrer M, Stevenson KE, Tausch E, Delgado J, Barbera-Mourelle A, Taylor-Weiner A, Bousquets-Mu?oz P, Diaz-Navarro A, Dunford A, Anand S, Kretzmer H, Gutierrez-Abril J, L?pez-Tamargo S, Fernandes SM, Sun C, Sivina M, Rassenti LZ, Schneider C, Li S, Parida L, Meissner A, Aguet F, Burger JA, Wiestner A, Kipps TJ, Brown JR, Hallek M, Stewart C, Neuberg DS, Mart?n-Subero JI, Puente XS, Stilgenbauer S, Wu CJ, Campo E, Getz GNature geneticsMolecular map of chronic lymphocytic leukemia and its impact on outcome. Nat Genet. 2022 11; 54(11):1664-1674.Nat Genet2022-08-04T00:00:002022Molecular map of chronic lymphocytic leukemia and its impact on outcome.36287248Jain N, Senapati J, Thakral B, Ferrajoli A, Thompson P, Burger J, Basu S, Kadia T, Daver N, Borthakur G, Konopleva M, Pemmaraju N, Parry E, Wu CJ, Khoury J, Bueso-Ramos C, Garg N, Wang X, Lopez W, Ayala A, O'Brien S, Kantarjian H, Keating M, Allison J, Sharma P, Wierda WBlood advancesA phase 2 study of nivolumab combined with ibrutinib in patients with diffuse large B-cell Richter transformation of CLL. Blood Adv. 2023 05 23; 7(10):1958-1966.Blood Adv2023-05-23T00:00:002023A phase 2 study of nivolumab combined with ibrutinib in patients with diffuse large B-cell Richter transformation of CLL.36617990Barr PM, Owen C, Robak T, Tedeschi A, Bairey O, Burger JA, Hillmen P, Dearden C, Grosicki S, McCarthy H, Li JY, Offner F, Moreno C, Jermain M, Zhou C, Hsu E, Szoke A, Kipps TJ, Ghia PFuture oncology (London, England)Many People With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Benefit From Ibrutinib Treatment Up To 8?Years: A Plain Language Summary. Future Oncol. 2023 01 09.Future Oncol2023-01-09T00:00:002023Many People With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Benefit From Ibrutinib Treatment Up To 8?Years: A Plain Language Summary.36865338Konopleva M, DiNardo C, Bhagat T, Baran N, Lodi A, Saxena K, Cai T, Su X, Skwarska A, Guerra V, Kuruvilla V, Konoplev S, Gordon-Mitchell S, Pradhan K, Aluri S, Collins M, Sweeney S, Busquet J, Rathore A, Deng Q, Green M, Grant S, Demo S, Choudhary G, Sahu S, Agarwal B, Spodek M, Thiruthuvanathan V, Will B, Steidl U, Tippett G, Burger J, Borthakur G, Jabbour E, Pemmaraju N, Kadia T, Komblau S, Daver N, Naqvi K, Short N, Garcia-Manero G, Tiziani S, Verma AResearch squareGlutaminase inhibition in combination with azacytidine in myelodysplastic syndromes: Clinical efficacy and correlative analyses. Res Sq. 2023 Feb 23.Res Sq2023-02-23T00:00:002023Glutaminase inhibition in combination with azacytidine in myelodysplastic syndromes: Clinical efficacy and correlative analyses.Authorship 1067982537016930Gordon MJ, Jones JE, George B, Peterson C, Burger JA, Jain N, Keating M, Wierda WG, Durand JB, Ferrajoli ACancerLong-term outcomes in patients with chronic lymphocytic leukemia treated with ibrutinib: Focus on hypertension and cardiovascular toxicity. Cancer. 2023 07 15; 129(14):2192-2200.Cancer2023-04-05T00:00:002023Long-term outcomes in patients with chronic lymphocytic leukemia treated with ibrutinib: Focus on hypertension and cardiovascular toxicity.Authorship 1073030537317991Roccograndi LM, Lovell AR, Ferrajoli A, Thompson PA, Burger JA, Wierda WG, Jain N, Rausch CRLeukemia & lymphomaIncidence of major bleeding in patients with chronic lymphocytic leukemia receiving ibrutinib and therapeutic anticoagulation. Leuk Lymphoma. 2023 09; 64(9):1554-1561.Leuk Lymphoma2023-06-15T00:00:002023Incidence of major bleeding in patients with chronic lymphocytic leukemia receiving ibrutinib and therapeutic anticoagulation.Authorship 1075106437457553Turcotte AE, Glass WF, Lin JS, Burger JALeukemia research reportsMembranous nephropathy in chronic lymphocytic leukemia responsive to ibrutinib: A case report. Leuk Res Rep. 2023; 20:100377.Leuk Res Rep2023-06-20T00:00:002023Membranous nephropathy in chronic lymphocytic leukemia responsive to ibrutinib: A case report.Authorship 107730210Authorship 1078525437585491Senapati J, Fiskus WC, Daver N, Wilson NR, Ravandi F, Garcia-Manero G, Kadia T, DiNardo CD, Jabbour E, Burger J, Short NJ, Alvarado Y, Jain N, Masarova L, Issa GC, Qiao W, Khoury JD, Pierce S, Miller D, Sasaki K, Konopleva M, Bhalla KN, Borthakur G, Pemmaraju NClinical cancer research : an official journal of the American Association for Cancer ResearchPhase I Results of Bromodomain and Extra-Terminal Inhibitor PLX51107 in Combination with Azacitidine in Patients with Relapsed/Refractory Myeloid Malignancies. Clin Cancer Res. 2023 11 01; 29(21):4352-4360.Clin Cancer Res2023-11-01T00:00:002023Phase I Results of Bromodomain and Extra-Terminal Inhibitor PLX51107 in Combination with Azacitidine in Patients with Relapsed/Refractory Myeloid Malignancies.37717577Koehrer S, Burger JAActa haematologicaChronic Lymphocytic Leukemia: Disease Biology. Acta Haematol. 2024; 147(1):8-21.Acta Haematol2023-09-16T00:00:002023Chronic Lymphocytic Leukemia: Disease Biology.Authorship 1079815837767562Safa FM, Rasmussen T, Fontan L, Xia M, Melnick A, Wiestner A, Lobelle-Rich P, Burger JA, Mouawad Y, Safah H, Flemington EK, Saba NSHaematologicaProfiling the activity of the para-caspase MALT1 in B-cell acute lymphoblastic leukemia for potential targeted therapeutic application. Haematologica. 2023 Sep 28.Haematologica2023-09-28T00:00:002023Profiling the activity of the para-caspase MALT1 in B-cell acute lymphoblastic leukemia for potential targeted therapeutic application.Authorship 108140932true1ProfessorProfessortrue1ProfessorProfessortrue1ProfessorProfessortrue1ProfessorProfessortrue1ProfessorProfessortrue1Associate ProfessorAssociate Professortrue1ProfessorProfessortrue1Assistant ProfessorAssistant Professor24516016Bulian P, Shanafelt TD, Fegan C, Zucchetto A, Cro L, N?ckel H, Baldini L, Kurtova AV, Ferrajoli A, Burger JA, Gaidano G, Del Poeta G, Pepper C, Rossi D, Gattei VJournal of clinical oncology : official journal of the American Society of Clinical OncologyCD49d is the strongest flow cytometry-based predictor of overall survival in chronic lymphocytic leukemia. J Clin Oncol. 2014 Mar 20; 32(9):897-904.J Clin Oncol2014-02-10T00:00:002014CD49d is the strongest flow cytometry-based predictor of overall survival in chronic lymphocytic leukemia.